Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →

Ovarian Carcinosarcoma

A rare, aggressive ovarian cancer with both carcinoma and sarcoma features. Management is individualized and often complex.

Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Sep 2026 · site editor · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Sep 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
40 published studies that name Ovarian Carcinosarcoma19 human studies approved & graded (trial, observational, or meta-analysis)17 human clinical studies in the Ovarian Carcinosarcoma corpus215 source documents in the Ovarian Carcinosarcoma corpus

last checked September 8, 2026

Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Standard care - guideline-backed
  • Primary cytoreductive surgery
  • Goal: complete or optimal cytoreduction (<1 cm residual disease), as residual tumor volume
  • Hysterectomy with bilateral salpingo-oophorectomy and omentectomy
  • In advanced disease, radical debulking (bowel resection, splenectomy, diaphragm stripping)
  • Interval debulking (surgery after initial chemotherapy)
  • Fertility-sparing surgery
  • Not routinely used in frontline management, but
  • Pelvic or para-aortic radiation
  • Stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT)
  • Radiation
  • Use cautiously in heavily pre-treated patients due to marrow reserve and bowel tolerance
  • Platinum/taxane doublet (e.g., carboplatin + paclitaxel)
  • Response rates
  • Ifosfamide/doxorubicin or gemcitabine/docetaxel regimens
  • PARP inhibitors (e.g., olaparib, niraparib)
  • Immunotherapy (PD-1/PD-L1 inhibitors)
  • Bevacizumab (anti-VEGF) has been used in select cases; timing around surgery and wound healing
  • Clinical trial enrollment
  • Platinum/Taxane (epithelial-leaning)
  • Ifosfamide/Doxorubicin variants (sarcomatous-leaning)
  • Gemcitabine/Docetaxel (sarcoma option) (recurrent/palliative)
  • PARP inhibitor maintenance (contextual) (BRCA/HRD-positive)
  • MSI-high, dMMR, or TMB-high tumors: these subsets
  • PD-1/PD-L1 expression: variable across OCS
  • HER2 overexpression/amplification: uncommon but actionable
  • EGFR and related receptor tyrosine kinases: occasionally expressed in carcinosarcomas. Small-molecule inhibitors have shown activity in other tumors, but OCS data
  • VEGF/angiogenesis signaling: bevacizumab has been incorporated in some regimens for epithelial ovarian cancer and has been tried in OCS. Benefits
Guideline / FDA options - context-specific
  • Homologous recombination deficiency (HRD) and BRCA1/2 mutations: when present, PARP inhibitors (olaparib, niraparib, rucaparib)
  • PI3K/AKT/mTOR alterations: reported in some OCS cases. mTOR inhibitors (everolimus, temsirolimus) and PI3K inhibitors
  • Combination approaches (e.g., PARP + PD-1 blockade, anti-angiogenic + checkpoint inhibitors)
  • Adoptive T-cell therapy, bispecific antibodies, and oncolytic viruses
  • Carboplatin
  • pembrolizumab
  • doxorubicin
  • cisplatin
  • relacorilant
Supportive care - symptom / survivorship support
  • Pain management: multimodal approach (opioids, neuropathic agents like gabapentin, NSAIDs if safe)
  • Nausea/vomiting: 5-HT3 antagonists, NK1 inhibitors, dexamethasone; complementary approaches
  • Ascites management: paracentesis for comfort
  • Bowel obstruction: dietary modification, anti-motility or pro-motility drugs (case-specific), stents, or surgical diversion in select cases
  • Nutritional optimization: early dietitian involvement to preserve weight, muscle mass, and protein intake
  • Consider specialized diets (ketogenic, fasting-mimicking) only in coordination with oncology to avoid malnutrition
  • Oral supplementation: vitamin D, omega-3 fatty acids, and probiotics
  • Physical therapy and mobility support: maintain baseline function, reduce fall risk, and preserve independence
  • Prehabilitation (before surgery) and rehabilitation (after surgery/chemo)
  • Fatigue management: graded exercise, sleep hygiene, mindfulness strategies
  • Psychological support: counseling, peer support groups, or integrative practices (meditation, music therapy)
  • Spiritual care: chaplaincy or faith-based support
  • Family/caregiver support: education on prognosis, treatment side effects, and home care planning
  • Oral mucositis prevention: photobiomodulation (low-level laser), glutamine, or cryotherapy during infusion
  • Skin care: barrier creams, antifungal powders, and wound care support for radiation or chemo-induced dermatitis
  • Peripheral neuropathy: consider acupuncture, cryotherapy on hands/feet during taxane infusions, and supplements like alpha-lipoic acid or B-vitamins (if no contraindications)
  • Early palliative care involvement improves quality of life, reduces ER visits, and aligns treatment intensity with patient goals
  • Hospice transition
  • Advance care planning: proactive discussion of goals, advance directives, and treatment preferences to guide care
  • Sleep support: melatonin, relaxation techniques, or non-habit-forming sleep aids as appropriate
  • Financial navigation: oncology social worker assistance for medication costs, travel, or disability paperwork
  • Complementary therapies: massage, aromatherapy, yoga, and mindfulness practices—integrated carefully with medical oversight
Studied, not standard - investigational
  • trabectedin
  • PLAP
  • chemotherapy
  • Cyclosporin A
  • CNTO 95
  • eribulin
  • ifosfamide + paclitaxel
  • niraparib
  • trastuzumab deruxtecan
  • HER2-targeted therapy
  • elimusertib
  • vascular endothelial growth factor inhibitors
  • WT1 mRNA-loaded dendritic cell immunotherapy
  • solitomab
  • cytoreductive surgery
  • hyperthermic intraperitoneal chemotherapy
  • cardiophrenic lymph node resection
  • synthetic arterial graft reconstruction
  • lymphadenectomy
  • Docetaxel
  • cis-platinum-based combination chemotherapy
  • carboplatin + paclitaxel
  • liver mobilization + the Pringle maneuver
  • surgery
  • ReACp53
  • Staurosporine
  • Flavopiridol
  • BS-181 HCl
  • tyrosine kinase inhibitors
  • bilateral prophylactic oophorectomy
  • secondary cytoreductive surgery (SCS)
  • tertiary debulking surgery
  • paclitaxel
  • cyclophosphamide
  • dacarbazine
  • Trastuzumab-Deruxtecan (T-Dxd)

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Ovarian Carcinosarcoma.

Treatment map: Ovarian Carcinosarcoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

72
Interventions
27
Standard of care
10
Tested in people
1
Lab / animal
25
Named in lit.
7
Classes
Standard of care (27) Guideline option (9) Tested in people (10) Lab / animal only (1) Named in the literature (25)

Tested in people, by trial phase: Phase II ×2 · Phase I ×1 · phase not reported ×7

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
6
—
1
—
9
Radiotherapy
5
—
—
—
—
Chemotherapy
8
3
5
—
5
Targeted therapy
5
4
3
1
4
Immunotherapy
3
2
—
—
2
Supplements & natural agents
—
—
1
—
—
Other
—
—
—
—
5

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (36)
Surgery & procedures
Primary cytoreductive surgery
Primary cytoreductive surgery is the cornerstone of management, similar to high-grade epithelial ovarian cancer.
CurativeStandardCurated
Goal: complete or optimal cytoreduction (<1 cm residual disease), as residual tumor volume
Goal: complete or optimal cytoreduction (<1 cm residual disease), as residual tumor volume is the strongest predictor of survival.
CurativeStandardCurated
Hysterectomy with bilateral salpingo-oophorectomy and omentectomy
Hysterectomy with bilateral salpingo-oophorectomy and omentectomy are standard, often with peritoneal biopsies and nodal assessment.
CurativeStandardCurated
In advanced disease, radical debulking (bowel resection, splenectomy, diaphragm stripping)
In advanced disease, radical debulking (bowel resection, splenectomy, diaphragm stripping) may be required.
CurativeStandardCurated
Interval debulking (surgery after initial chemotherapy)
Interval debulking (surgery after initial chemotherapy) may be considered if complete resection is not feasible at diagnosis.
CurativeStandardCurated
Fertility-sparing surgery
Fertility-sparing surgery is generally not advised due to aggressiveness, except in ultra-rare Stage IA cases with strong patient preference.
CurativeStandardCurated
Radiotherapy
Not routinely used in frontline management, but
Not routinely used in frontline management, but can play a role in symptom control.
—StandardCurated
Pelvic or para-aortic radiation
Pelvic or para-aortic radiation may help with bulky nodal disease or unresectable pelvic recurrence.
—StandardCurated
Stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT)
Stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) may be considered for oligometastatic disease (bone, brain, or liver lesions).
Advanced / metastaticStandardCurated
Radiation
Radiation can palliate bleeding, pain, or obstruction when systemic therapy options are exhausted.
PalliativeStandardCurated
Use cautiously in heavily pre-treated patients due to marrow reserve and bowel tolerance
Use cautiously in heavily pre-treated patients due to marrow reserve and bowel tolerance.
—StandardCurated
Chemotherapy
Platinum/taxane doublet (e.g., carboplatin + paclitaxel)
Platinum/taxane doublet (e.g., carboplatin + paclitaxel) is most commonly used, borrowed from epithelial ovarian cancer protocols.
—StandardCurated
Response rates
Response rates are lower than in pure epithelial ovarian cancer, reflecting sarcomatous resistance biology.
—StandardCurated
Ifosfamide/doxorubicin or gemcitabine/docetaxel regimens
Ifosfamide/doxorubicin or gemcitabine/docetaxel regimens are sometimes considered in sarcoma-predominant or recurrent settings, but evidence is limited.
Advanced / metastaticStandardCurated
Clinical trial enrollment
Clinical trial enrollment is strongly encouraged given limited standard options.
—StandardCurated
Platinum/Taxane (epithelial-leaning)
Most common backbone borrowed from epithelial ovarian cancer; typically carboplatin + paclitaxel. Response rates lower than HGSOC due to sarcomatous resistance.
—StandardCurated
Ifosfamide/Doxorubicin variants (sarcomatous-leaning)
Anthracycline/ifosfamide combinations used in soft-tissue sarcomas; sometimes considered in sarcoma-predominant OCS. Limited evidence, more toxicity, but an option in select cases.
—StandardCurated
Gemcitabine/Docetaxel (sarcoma option) (recurrent/palliative)
Commonly used in uterine and soft-tissue sarcomas; anecdotal use in OCS with sarcomatous dominance or recurrence.
Advanced / metastaticStandardCurated
PARP inhibitor maintenance (contextual) (BRCA/HRD-positive)
Not a backbone per se, but can serve as maintenance in BRCA/HRD-positive patients after platinum response. Resistance often emerges.
MaintenanceStandardCurated
Carboplatin
FDA-approved for this cancer.
—Guideline option
doxorubicin
FDA-approved for this cancer.
—Guideline option
cisplatin
FDA-approved for this cancer.
—Guideline option
Targeted therapy
PARP inhibitors (e.g., olaparib, niraparib)
PARP inhibitors (e.g., olaparib, niraparib) may be used in BRCA-mutated or HRD-positive tumors, though data in OCS are anecdotal.
—StandardCurated
Bevacizumab (anti-VEGF) has been used in select cases; timing around surgery and wound healing
Bevacizumab (anti-VEGF) has been used in select cases; timing around surgery and wound healing is critical.
—StandardCurated
Homologous recombination deficiency (HRD) and BRCA1/2 mutations: when present, PARP inhibitors (olaparib, niraparib, rucaparib)
Homologous recombination deficiency (HRD) and BRCA1/2 mutations: when present, PARP inhibitors (olaparib, niraparib, rucaparib) may be considered. Evidence in OCS is extrapolated from epithelial ovarian cancer; responses are anecdotal. Resistance often develops through HR restoration mutations.
—Guideline optionCurated
HER2 overexpression/amplification: uncommon but actionable
HER2 overexpression/amplification: uncommon but actionable. Trastuzumab or newer HER2-targeted agents (trastuzumab deruxtecan) could be considered in select cases, usually extrapolated from gastric/breast data.
—StandardCurated
EGFR and related receptor tyrosine kinases: occasionally expressed in carcinosarcomas. Small-molecule inhibitors have shown activity in other tumors, but OCS data
EGFR and related receptor tyrosine kinases: occasionally expressed in carcinosarcomas. Small-molecule inhibitors have shown activity in other tumors, but OCS data are sparse. Adaptive bypass (PI3K/AKT, MAPK) usually limits durability.
—StandardCurated
VEGF/angiogenesis signaling: bevacizumab has been incorporated in some regimens for epithelial ovarian cancer and has been tried in OCS. Benefits
VEGF/angiogenesis signaling: bevacizumab has been incorporated in some regimens for epithelial ovarian cancer and has been tried in OCS. Benefits are context-dependent; risk of wound-healing complications and hypertension requires careful timing.
—StandardCurated
PI3K/AKT/mTOR alterations: reported in some OCS cases. mTOR inhibitors (everolimus, temsirolimus) and PI3K inhibitors
PI3K/AKT/mTOR alterations: reported in some OCS cases. mTOR inhibitors (everolimus, temsirolimus) and PI3K inhibitors are under study in basket trials. Resistance often emerges via pathway redundancy (MAPK cross-talk).
—Guideline optionCurated
Adoptive T-cell therapy, bispecific antibodies, and oncolytic viruses
Adoptive T-cell therapy, bispecific antibodies, and oncolytic viruses are experimental but conceptually relevant given the tumor’s immune-evasive biology.
—Guideline optionCurated
relacorilant
FDA-approved for this cancer.
—Guideline option
Immunotherapy
Immunotherapy (PD-1/PD-L1 inhibitors)
Immunotherapy (PD-1/PD-L1 inhibitors) is investigational; may be considered if MSI-H, dMMR, or high TMB is documented.
—StandardCurated
MSI-high, dMMR, or TMB-high tumors: these subsets
MSI-high, dMMR, or TMB-high tumors: these subsets may qualify for PD-1 blockade (e.g., pembrolizumab) under tumor-agnostic approvals. Such cases are rare in OCS, but dramatic responses are occasionally reported.
—StandardCurated
PD-1/PD-L1 expression: variable across OCS
PD-1/PD-L1 expression: variable across OCS; may guide trial eligibility. Monotherapy responses tend to be modest; combination approaches (chemo + checkpoint blockade, or dual checkpoint strategies) may be more effective.
—StandardCurated
Combination approaches (e.g., PARP + PD-1 blockade, anti-angiogenic + checkpoint inhibitors)
Combination approaches (e.g., PARP + PD-1 blockade, anti-angiogenic + checkpoint inhibitors) may overcome resistance mechanisms and are being explored in clinical trials.
—Guideline optionCurated
pembrolizumab
FDA-approved for this cancer.
—Guideline option

Established care shown from OncoForge editorial curation · reviewed September 12, 2025 — authoritative citations (NCI PDQ / FDA) are being added.

Supportive care (22)
  • Pain management: multimodal approach (opioids, neuropathic agents like gabapentin, NSAIDs if safe). Consider palliative care input early for optimization.
  • Nausea/vomiting: 5-HT3 antagonists, NK1 inhibitors, dexamethasone; complementary approaches include ginger, acupuncture, and olanzapine in refractory cases.
  • Ascites management: paracentesis for comfort; indwelling catheters or albumin support for recurrent fluid accumulation.
  • Bowel obstruction: dietary modification, anti-motility or pro-motility drugs (case-specific), stents, or surgical diversion in select cases.
  • Nutritional optimization: early dietitian involvement to preserve weight, muscle mass, and protein intake; address cachexia proactively.
  • Consider specialized diets (ketogenic, fasting-mimicking) only in coordination with oncology to avoid malnutrition.
  • Oral supplementation: vitamin D, omega-3 fatty acids, and probiotics may support resilience, but timing with chemo is critical.
  • Physical therapy and mobility support: maintain baseline function, reduce fall risk, and preserve independence.
  • Prehabilitation (before surgery) and rehabilitation (after surgery/chemo) can improve tolerance of aggressive treatment.
  • Fatigue management: graded exercise, sleep hygiene, mindfulness strategies; screen for anemia or thyroid dysfunction.
  • Psychological support: counseling, peer support groups, or integrative practices (meditation, music therapy).
  • Spiritual care: chaplaincy or faith-based support can improve coping and quality of life.
  • Family/caregiver support: education on prognosis, treatment side effects, and home care planning.
  • Oral mucositis prevention: photobiomodulation (low-level laser), glutamine, or cryotherapy during infusion.
  • Skin care: barrier creams, antifungal powders, and wound care support for radiation or chemo-induced dermatitis.
  • Peripheral neuropathy: consider acupuncture, cryotherapy on hands/feet during taxane infusions, and supplements like alpha-lipoic acid or B-vitamins (if no contraindications).
  • Early palliative care involvement improves quality of life, reduces ER visits, and aligns treatment intensity with patient goals.
  • Hospice transition: should be considered when disease-directed therapy no longer provides benefit or is intolerable.
  • Advance care planning: proactive discussion of goals, advance directives, and treatment preferences to guide care.
  • Sleep support: melatonin, relaxation techniques, or non-habit-forming sleep aids as appropriate.
  • Financial navigation: oncology social worker assistance for medication costs, travel, or disability paperwork.
  • Complementary therapies: massage, aromatherapy, yoga, and mindfulness practices—integrated carefully with medical oversight.
Investigational & adjunct compounds — detail (36)
Phase II trial (2)
Cyclosporin Atrabectedin
Phase I trial (1)
CNTO 95
Meta-analysis (1)
lymphadenectomy
Named in the literature
PLAPeribulinifosfamide + paclitaxelHER2-targeted therapyelimusertibvascular endothelial growth factor inhibitorsWT1 mRNA-loaded dendritic cell immunotherapysolitomabcytoreductive surgeryhyperthermic intraperitoneal chemotherapycardiophrenic lymph node resectionsynthetic arterial graft reconstructionDocetaxelcis-platinum-based combination chemotherapycarboplatin + paclitaxelliver mobilization + the Pringle maneuversurgeryReACp53StaurosporineFlavopiridolBS-181 HCltyrosine kinase inhibitorsbilateral prophylactic oophorectomy· BRCA1 or BRCA2 variantssecondary cytoreductive surgery (SCS)tertiary debulking surgery
Lab / animal only
niraparib

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Ovarian Carcinosarcoma
A monthly email when the research changes — $10/mo. Manage follows
Follow Ovarian Carcinosarcoma

Ask about Ovarian Carcinosarcoma

Answers come only from the cited sources on this page — with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

10 sections — tap any heading to expand its cited detail. Key points are above.

Overview18 points
Show 2 lab & early-research findings
  • Sources mention ovarian carcinosarcoma as an ovarian cancer histology, including a comprehensive case report and discussion of possible benefit from lymphadenectomy in this histology. [101][102][103][104]4 sources
  • In a reported case, presentation included a 6-month history of progressive slurred speech, vertigo, unsteadiness, and falls. [98]
Epidemiology17 points
  • Ovarian carcinosarcoma is reported as about 1% to 4% of ovarian cancers, ovarian tumors, or ovarian malignancies in multiple sources; some sources give narrower estimates of 1% to 2%, 1% to 3%, 2%, or less than 1%. [2][4][3][6][7][82][8][10][92][11][20][22][23][25][26][27][28][105][106][55][107][59][108][109][68]25 sources
  • Sources describe ovarian carcinosarcoma/OMMMT as often presenting at advanced stage. One systematic review reported 59.64% of patients in FIGO stage III, another review said the majority present at advanced stages (often exceeding 60%), and one series reported 70% with FIGO stage III-IV disease. [1][6][8][9][19][17][110][13][31][36][111][112][39][41][45][43][48][49][47][51][54][107][113][59][32]25 sources
  • One systematic review reported the highest incidence age as 60 to 65 years and found that 82% of reported patients were menopausal; other cited sources describe ovarian carcinosarcoma as occurring mainly or most commonly in postmenopausal or elderly women, including with a peak in the sixth decade. [1][19][88][6][8][9][20][94][114][48][107][64][68][70][72]15 sources
  • One review states that up to 90% of ovarian carcinosarcomas have disease spread beyond the ovary. The cited sources do not support the added statement that this usually involves the peritoneum or that more than half present with metastatic disease at diagnosis. [30][64][45]3 sources
  • In one retrospective series, the mean overall survival was 15.4 months, and another review reported a median survival of 18 months and a 5-year survival rate of only 8%. [115][75][94]3 sources
  • One review states that fewer than 400 cases of primary ovarian carcinosarcoma had been reported in the English literature, and another describes only a few cases reported in Taiwan. [84][116]
  • In one ultrasound series, 67/91 patients were symptomatic and pain was the most common complaint; bilateral lesions were observed in 46/91 patients. [90]
  • In one comparative study, 67% of patients with ovarian carcinosarcoma had lymph node metastasis. [117]
  • In that analysis, non-Hispanic Black women with ovarian carcinosarcoma were more common in the South and more likely to have a comorbidity score of at least 1, low neighborhood income, and Medicaid or no insurance. [100]
  • In the reported series, patients with ovarian sarcoma had a mean age of 54.3 ± 10.3 years and 16 of the 24 patients were postmenopausal. [99]
  • In one population-based analysis, 1,763 of 27,737 ovarian tumors were carcinosarcomas, and in one institutional cohort, 11 of 822 ovarian cancer patients had ovarian carcinosarcoma histology. [31][26]
  • In one SEER analysis, 924 of 3683 women had ovarian carcinosarcoma, and in another SEER analysis, women with ovarian carcinosarcoma had a worse five-year disease-specific survival rate than women with high grade papillary serous ovarian carcinoma. [118][119]
  • In a Texas Cancer Registry series of 52 women with primary ovarian carcinosarcoma, the prevalence of distant metastasis at diagnosis was reported as 66% in white patients and 60% in black patients. [120]
  • In a Korean registry study, ovarian carcinosarcoma accounted for 1.5% of epithelial ovarian cancers, with an age-standardized incidence rate of 0.064 per 100,000 women and an annual percent change of 5.86. [110]
  • In a population-based analysis, ovarian carcinosarcoma diagnosis remained under 5% in both races and all ages. [100]
  • In a retrospective cohort of 90 patients, the median age at diagnosis was 58 years (range 40–86) and 92% were postmenopausal. [121]
Show 1 lab & early-research finding
  • Sources report abdominal pain as the most common symptom in one systematic review. Other cited case reports/reviews mention pelvic or abdominal pain, bloating, compression symptoms, pelvic mass, lower abdominal pain, increased abdominal circumference, and abdominal distension. [1][19][49][51][53][54][64][65][109]9 sources
Key biomarkers50 points
  • TP53 mutations are often detected in OCS, and recent reviews describe OCS as often copy number high with frequent TP53 mutation. [6][7][8][92][12][122][59][50][52]9 sources
  • Some OCS tumors harbor homologous recombination pathway alterations such as BRCA1 or BRCA2 mutations, and homologous recombination deficiency has been reported in some ovarian carcinosarcomas. [6][7][44][43][51][50][53]7 sources
  • A review states that some ovarian carcinosarcomas have shown limited HER2 expression, and case material has reported HER2 expression in an ovarian carcinosarcoma. [12][53][123]3 sources
  • Sources report TP53 abnormalities in ovarian carcinosarcoma, including p53 mutation-pattern staining in one report and a somatic TP53 mutation in another report. [50][52][60]3 sources
  • A review states that up to 64% of ovarian carcinosarcomas may harbor homologous recombination deficiency. [6][124]
  • Recent reviews report frequent TP53 mutation in ovarian carcinosarcoma and describe it as often copy number high. [92][12]
  • A pathology study reported SMARCA4 loss of protein expression in all 5 serous/homologous OCS cases it examined. [82]
  • In a single-cell transcriptomics study, epithelial subcluster 4 showed high BRCA1 and TOP2A expression and was related to drug resistance and cell cycle, while mesenchymal subcluster C14 showed elevated CYP24A1, COL23A1, CCK, BMP7, PTN, WIF1, and IGF2 expression. [125]
  • In one molecular study of carcinosarcoma, TP53 mutations were most common, with less common mutations in RB1, MET, KRAS, PTEN, and KIT. [126]
  • One study found that intraepithelial PD-L1 positivity was associated with positive ascites fluid, and reported no significant difference in PD-L1 expression or CD8+ T lymphocyte counts between intraepithelial and mesenchymal components. [25]
  • A 2024 MRI review states that the Mille-feuille sign can be seen in OCS, and also reports that intratumoral hemorrhage, margin irregularity, unilateral adnexal mass, low ADC values, and low serum CEA levels were more frequent or lower in OCS than in ovarian metastases from colorectal carcinoma. [127]
  • One organoid study reported hyperstaining of p53 protein and a TP53 mutation resulting in deletion of N131. [128]
  • In one recurrent case, an increased IGF-II/IGF-I ratio was suggestive of non-islet cell tumor hypoglycemia. [129]
  • In one ovarian MMMT with neuroectodermal differentiation, the neuroectodermal component showed immunoreactivity for glial fibrillary acidic protein, synaptophysin, and S100 protein. [72]
  • In one dog ovarian MMMT, the carcinomatous elements were immunohistochemically positive for cytokeratin AE1/AE3, CK7, vimentin, and estrogen receptors, while the sarcomatous cells were positive for vimentin but negative for cytokeratins and the chondrocytes expressed S-100 protein. [130]
  • DNA ploidy analysis was performed on the various components of one tumor and compared with additional MMMT cases and ovarian immature teratomas. [72]
  • One report found positivity for both neural and epithelial markers in the neuroectodermal cells. [78]
  • In one series, the epithelial component showed epithelial membrane antigen positivity and the fibrosarcomatous area showed vimentin positivity, and S-100 protein was positive in two cases with chondrosarcomatous differentiation. [131]
  • A report of ovarian carcinosarcoma found clonal loss of the wild-type BRCA2 allele and the same somatic TP53 mutation in both histologic components. [76]
  • In one germline study, 20% of patients with ovarian carcinosarcoma had germline pathogenic variants; BRCA1, BRCA2, RAD51C, MSH2, and MSH6 germline pathogenic variants showed biallelic loss in tumors, and all evaluable high-penetrance germline pathogenic variants had biallelic loss. [14]
  • Reactivity for VEGF and CD45RO was observed in four and two tumor specimens, respectively. [132]
  • In one study, p53 protein and Ki67 immunoreactivity were not statistically significant prognostic indicators, and none of the other clinicopathologic factors listed was a statistically significant prognostic indicator. [38]
  • One report found steroid receptor-positive and -negative tumors in both leiomyosarcoma and uterine or ovarian carcinosarcoma, and suggested that steroid receptors should be analyzed in all gynecologic sarcomas. [133]
  • PAS-positive, diastase-resistant hyaline droplets were found in 21 of 22 ovarian malignant mixed mesodermal tumors, including carcinosarcoma, and immunoperoxidase staining for alpha-fetoprotein was consistently negative while droplets and cell cytoplasm reacted strongly with anti-alpha 1-antitrypsin. [134]
  • In the same study, higher TUBB3 expression levels were detected in uterine versus ovarian fresh-frozen carcinosarcoma tissues (P<0.05). [95]
  • A review of epithelial ovarian cancers states that rare histotypes have substantial knowledge gaps and that additional targeted therapeutic strategies will require a detailed understanding of the molecular landscape in each histotype. [104]
  • Next-generation sequencing in that case identified pathogenic alterations in p53, KRAS, and CDKN2A and amplification of the CRKL gene. [135]
  • In a series of gynecologic mesonephric-like carcinosarcomas (MLCS), all evaluated cases (6/6) harbored KRAS point mutations in codon 12. [136]
  • Those MLCS cases had low mutational burden (<10 mutations/Mb) and were microsatellite stable. [136]
  • In sequencing of potential morphologic mimics (which included 8 ovarian carcinosarcomas), none showed STK11 inactivating alterations. [137]
  • One retrospective series reported elevated CA125 in 4 of 5 patients and elevated CA153 in 3 of 5 patients. [57]
  • Case-control studies suggest that women with BRCA1 and BRCA2 variants have improved responses to chemotherapy, which the authors note may relate to a deficient homologous DNA repair mechanism. [138]
Show 18 lab & early-research findings
  • The NEYS cell line produced carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 125. [139]
  • In one small series, all specimens were negative for CD34, c-erbB-2, estrogen, and progesterone receptor expression, five tumors overexpressed p53, and four specimens demonstrated a positive staining for Ki67. [132]
  • A review of a human ovarian carcinosarcoma cell line concluded that the tumor line is comprised of epithelial cells capable of multidirectional differentiation, and the parent line JoN showed keratin expression while vimentin was present in both sublines. [140]
  • A mouse model study reported that K-ras mutation and p53 deletion in ovarian surface epithelium gave rise to ovarian lesions and ovarian carcinosarcomas, and that double mutant ovaries formed high-grade, poorly differentiated ovarian carcinosarcomas that were widely metastatic. [141]
  • One study reported higher TUBB3 expression levels in uterine carcinosarcoma cell lines and fresh-frozen tissues than in ovarian carcinosarcoma (P<0.05). [95]
  • In one cell-line and tissue study, TUBB3 expression was significantly higher in primary uterine carcinosarcoma cell lines than in ovarian carcinosarcoma cell lines. [95]
  • CA125 was abnormal in 88.68% of patients with recorded CA125 status in the systematic review, and serum CA-125 is reported in case reports and reviews as elevated in some patients or in the majority of cases. [1][114][46][45][85]5 sources
  • Case reports describe immunohistochemical positivity for markers including WT1, CK7, ER, Pax8, and p53 in ovarian carcinosarcoma tissues or components, and one report identified a TP53 mutation. [51][54][52][55][113]5 sources
  • One case report found diffuse p53 and p16 positivity in the STIC, high-grade serous carcinoma component, and chondrosarcoma component, with an identical TP53 mutation in all three components. [85][142]
  • One case report found epithelial membrane antigen positive in a few cells of the sarcomatous component, and the same report described the DNA ploidy pattern of the primary ovarian tumor as diploid, with an additional aneuploid subpopulation in the recurrent tumor. [109][143]
  • A 2026 case report found identical PIK3CA H1047R and CSF1R alterations in both epithelial and mesenchymal components of one ovarian carcinosarcoma, and interpreted the identical mutations as evidence of a common clonal origin. [3]
  • A case report found the carcinomatous component positive for cytokeratin and estrogen receptor and negative for progesterone receptor, while the sarcomatous component was positive for vimentin. [109]
  • One case report described strong immunohistochemical reactivities for desmin, cytoplasmic WT1, p16, and vimentin in the sarcomatoid component, and the epithelial component stained for AE1/AE3 cytokeratin, focally for p16 and p53, for nuclear WT1, and weakly for vimentin. [144]
  • A case report found serous tubal intraepithelial carcinoma in both fallopian tubes. [144]
  • One case report found the malignant melanoma focus was positive for S-100, HMB-45, and pan-melanoma cocktail, and negative for synaptophysin and neuron-specific enolase. [145]
  • One case report found ganglioneuroblastoma-like cells were positive for neural markers synaptophysin, S-100 protein, and neuron-specific enolase. [71]
  • One case report found no tumor immunoreactivity to alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and inhibin. [71]
  • One source reports a germline pathogenic BRCA2 variant in a patient with ovarian carcinosarcoma. [146]
Biology & pathways55 points
  • Ovarian carcinosarcomas are described as biphasic tumors with epithelial and mesenchymal components. [31][122][61][64][49]5 sources
  • The sources describe epithelial-to-mesenchymal transition as a proposed mechanism in OCS sarcomatogenesis. [8][82]
  • STIC is discussed as a proposed precursor lesion for some ovarian carcinosarcomas. [42][45]
  • The tumors are described as containing both malignant epithelial and mesenchymal elements. [61][64]
  • The sources describe the histogenesis of ovarian carcinosarcoma as controversial or obscure. [147][143]
  • No pathognomonic ultrasound sign of ovarian carcinosarcoma was found. [90]
  • All ovarian carcinosarcomas in one ultrasound series contained solid components, and most were described as solid or multilocular-solid. [90]
  • In one MRI comparison study, stained-glass appearance, hemorrhage, necrosis, and endometriosis were more common in ovarian carcinosarcoma than in high-grade serous carcinoma. [148]
  • One study found that p53 wild-type tumors were largely driven by KRAS mutations. [81]
  • The same study states that YAP1 is located downstream of the TGFβ and Hippo signaling pathways. [82]
  • The single-cell transcriptomics study identified FGF and PTN signaling as the main pathways contributing to communication between epithelial and mesenchymal cells. [125]
  • The scoping review states that the two most accepted theories of origin are the collision and conversion theories. [10]
  • A review reported evidence of homologous recombination deficiency in ovarian carcinosarcoma. [12]
  • One study of ovarian carcinosarcoma evaluated PD-L1 expression and reported that mesenchymal PD-L1-negative expression seemed to be associated with better survival; it also stated that immunotherapy targeting the PD-L1 pathway could be used in OCS. [25]
  • A sequencing study suggested a role for histone H2A and H2B mutations in epithelial-mesenchymal transition and sarcomatous transformation. [149]
  • One report states that the fallopian tube has been proposed as an origin for a majority of pelvic or ovarian high-grade serous adenocarcinomas and described adjacent serous tubal intraepithelial carcinoma in its case. [28]
  • The sarcomatous components in one small immunohistochemical series did not express E-cadherin or β-catenin, while carcinomatous components expressed both with reduced expression compared with endometrioid ovarian carcinomas. [150]
  • The same series suggested that cells in the carcinomatous component continuously transform into sarcomatous cells during tumor growth. [150]
  • Extravascular migratory metastasis was observed in an ovarian carcinosarcoma and was proposed as a hitherto unrecognized mechanism of tumor spread in gynecological carcinosarcomas. [151]
  • The perivascular malignant cells in EVMM-positive cases showed more consistent SMA and laminin immunoreactivity than the non-vascular tumor elements. [151]
  • The microscopic analysis suggested the epithelial component to drive the tumor, consistent with the monoclonal theory, and the recurrent setting showed a tendency toward sarcomatous differentiation during disease progression. [152]
  • The 1988 cell-line review concluded that the tumor line is comprised of epithelial cells capable of multidirectional differentiation. [140]
  • One review states that carcinosarcomas are carcinomas with epithelial–mesenchymal transition and heterologous differentiation. [85]
  • These tumors are described as mixed, mostly monoclonal tumors. [68]
  • One review states that the predominance of the stromal component aggravates the prognosis. [68]
  • One review suggests that the neuroectodermal component may arise from a separate clone or may evolve at an earlier stage of tumor development. [72]
  • One report states that the tumor phenotype comprised elements derived embryologically from the three germ layers. [153]
  • That report also states that the neoplasm coexisted with, and possibly originated from, a somatic tumor, namely a characteristic endometrioid adenocarcinoma. [153]
  • The same report says all neoplastic tissue patterns present were malignant per se without an apparent gradient of maturation or organoid structures. [153]
  • One report suggested that ovarian carcinosarcoma may arise as progression and clonal evolution of endometrioid adenocarcinoma. [143]
  • One report concluded that both histologic elements arose from the same progenitor cell. [76]
  • Another series speculated that ovarian mixed mesodermal tumor might originate from immature multipotential cells of surface epithelium and subcapsular connective tissue of the ovary. [131]
  • One report described the tumor as having prominent neuroectodermal elements mixed with epithelial and mesenchymal elements in an organoid fashion. [78]
  • One report stated that the tumor was heterogeneous on MR imaging and showed very high-intensity on T2-weighted images and iso-intensity on T1-weighted images with visible enhancement. [77]
  • A report noted that MR images provided useful information about the effect of chemotherapy. [154]
  • One source reports an ovarian carcinosarcoma with prominent neuroectodermal differentiation and mixed epithelial and mesenchymal components. [155]
  • The same report describes chondrosarcoma, rhabdomyosarcoma, and malignant neuroectodermal components in the tumor. [155]
  • The sarcomatous portion was described as prominently myxoid and pleomorphic with focal whorling and storiform pattern. [156]
  • The sources state that ovarian mesonephric-like carcinomas may arise from Müllerian carcinomas through mesonephric transdifferentiation. [157]
  • The authors report a procedure to perform genome-wide spatial analysis of mRNA in FFPE-fixed tissue sections and demonstrate its applicability by profiling mouse brain, two ovarian carcinosarcoma samples, human lung and kidney organoids, and a SARS-CoV-2–infected human lung biopsy specimen. [158]
  • Retrospective image review found irregular margins and inhomogeneous echogenicity of the solid components in all evaluated tumors. [90]
  • The study reported higher expression of mesenchymal genes such as VIM, ZEB1, and SNAI1 in the SMARCA4-knockdown group. [82]
  • One preclinical study reported that homologous recombination deficiency (HRD) has been demonstrated in >30% of ovarian and uterine carcinosarcomas. [159]
  • The mouse model study reported that K-rasG12D overexpression strongly induced cell proliferation, migration, and invasion in ovarian cancer cell lines. [141]
  • One ovarian carcinosarcoma PDX report described EGFR overexpression and amplification, detected EGFR phosphorylation, and implicated angiogenesis and insulin-like growth factor pathways by overexpression of VEGFC and IRS1. [160]
  • The NEYS cell line study supported the metaplasis theory as the cause of carcinosarcoma. [139]
  • The STK11 (LKB1) protein is part of a complex that regulates cell metabolism, growth, and apoptosis through activation of AMPK and downstream targets including mTORC1. [137]
  • One case report found diffuse p53 and p16 positivity in STIC, high-grade serous carcinoma, and chondrosarcoma components, and noted evidence suggesting monoclonality. [85][142]
  • One case report proposed that tubal carcinoma may be the origin for ovarian carcinosarcomas through an epithelial-mesenchymal transition. [28]
  • WT1 mRNA-loaded dendritic cell vaccination was reported to be feasible without toxicity in one patient with ovarian carcinosarcoma, and in one report disease progressed after four WT1 mRNA-loaded dendritic cell vaccines. [161]
  • One case report stated that gene study results suggested the sarcoma component may be differentiated from the cancer component. [55]
  • One case report suggests that carcinosarcomas may originate from the fallopian tube. [142]
  • One review notes rare case reports of primitive neuroectodermal tissue among heterologous elements. [70]
  • One case report describes an ovarian carcinosarcoma with malignant neuroectodermal components resembling immature teratoma. [71]
  • One case report describes melanocytic differentiation in an ovarian MMMT. [145]
Standard management24 points
  • Reported series describe surgery in most patients, and management commonly included cytoreductive surgery with adjuvant chemotherapy in many cases. [1][95][5][86][87][10][159][22][25][24][27][26][111][33][31][122][47][49][55][107][113][57][56][162][66][163][68][164][75][84][147][116][165][73][166][32][64][62][66][91]39 sources
  • Several reviews state that there is no established, standardized, or consensus treatment plan for ovarian carcinosarcoma, and that recommendations are limited because prospective studies and randomized trials are lacking. [124][15][16][13][167][21][122][59][50][55][107][113][85][56][163][160][51][53][86][80]20 sources
  • Sources describe platinum-based chemotherapy as the accepted/mainstay adjuvant treatment for ovarian carcinosarcoma, with carboplatin-paclitaxel commonly used and ifosfamide-containing regimens also reported; one review states carboplatin-paclitaxel is the most commonly used regimen. [124][51][53][54][50][27][30][57][60][43][26][73][116][84][147][62][64][168][169]19 sources
  • Management is often described as similar to high-grade serous or other epithelial ovarian cancers, and treatment guidelines are frequently extrapolated from epithelial ovarian cancer experience. [4][6][14][43][47][51][53][50][55][107][162][164][85][160]14 sources
  • No visible residual disease after surgery is described as an important prognostic factor, and complete or optimal cytoreduction is associated with improved survival outcomes in several series. [7][6][23][24][25][170][171][75][115][172][31][33][35][173]14 sources
  • The FIGO staging system used for ovarian cancer is also used for ovarian carcinosarcoma and related MMMT descriptions. [37][60][59][55][68]5 sources
  • Reported surgical management included procedures such as hysterectomy, salpingo-oophorectomy, omentectomy, appendectomy, lymph node dissection, biopsy, and tumor debulking in some cases. [1][55][85][64]4 sources
  • Sources describe radiotherapy as having an unclear or possible role in ovarian carcinosarcoma/MMMT; one review notes no overall survival benefit but reports decreased local recurrences in carcinosarcomas generally. [62][64][30][39]4 sources
  • One review states that the main treatment is complete surgical resection with staging, followed by postoperative chemotherapy for stage II-IV disease, with chemotherapy also considered for stage I MMMT. [62][68]
  • One review states that adjuvant chemotherapy is typically recommended after debulking surgery, and another describes platinum-based chemotherapy as the current accepted adjuvant treatment and mainstay of adjuvant systemic treatment. [56][27]
  • One retrospective series reported that early FIGO stage was the only independent prognostic factor for survival, and another reported that feasibility of cytoreductive surgery was a significant prognostic factor in stage III or IV disease. [39][173]
  • A Cochrane review found no trials and no evidence to inform decisions about neoadjuvant or adjuvant chemotherapy and radiotherapy regimens, or chemotherapy alone, for women with ovarian carcinosarcoma. [80]
  • One review states that the goal of surgery is comprehensive staging in early-stage disease and optimal cytoreduction in advanced-stage disease. [27]
  • One review states that the sources describe treatment as optimal cytoreduction and chemotherapy. [111]
  • One review states that the mainstay of treatment remains cytoreductive surgical effort for metastatic disease followed by platinum-based chemotherapy. [33]
  • One series reported cytoreductive surgery in 18 of 27 cases. [32]
  • One source states that guidelines for systemic treatment have been difficult to establish because ovarian carcinosarcoma is commonly excluded from prospective clinical trials. [59]
  • One source states that surgery, radiation therapy, and chemotherapy have been used to treat ovarian carcinosarcoma, alone or in combination. [91]
  • Peritoneal cytology is described as a diagnostic and staging tool in ovarian tumors, and one source includes a case of ovarian malignant mixed mullerian tumor in peritoneal washings. [174]
  • Careful correlation of peritoneal cytologic findings, cell-block preparations, and immunocytochemistry with cytohistologic features is described as crucial for correct tumor classification. [174]
  • Diagnostic and staging evaluation for ovarian epithelial cancer may include physical examination and history, pelvic examination, CA-125 assay, ultrasonography, CT, PET, MRI, chest x-ray, and biopsy. [138]
  • In a population-based analysis, women with ovarian carcinosarcoma were less likely to undergo surgery and less likely to achieve no gross residual disease with surgery if they were non-Hispanic Black. [100]
Show 2 lab & early-research findings
  • Sources describe surgery as mandatory in the reported fistulized ovarian carcinosarcoma case, and another case report describes cytoreductive surgery as the treatment performed. [47][49]
  • One source states that aggressive surgical treatment may play an important role; the cited splenic metastasis case report does not state that complete surgical resection offers the best chance of long-term survival. [164][122]
Treatments & compounds studied38 treatments

Chemotherapy

Show 2 lab & early-research entries

Targeted therapy

  • CNTO 95: CNTO 95 was studied in a phase I trial, and one patient with stable ovarian carcinosarcoma had a lesion that became undetectable by FDG-PET, with infusion-related fever reported in the trial. [193]
  • folate receptor alpha: Folate receptor alpha was observed in ovarian carcinosarcoma specimens and described as a potential therapeutic target. [194]
  • protein kinase inhibitors (library): A library of 240 kinase inhibitors was tested on patient-derived tumor organoids, and personalized responses were observed. [192]
  • tyrosine kinase inhibitors: The authors present individualized responses of patient-derived tumor organoids after exposure to 240 kinase inhibitors. [192]
Show 5 lab & early-research entries
  • niraparib: Niraparib maintenance therapy has been reported in isolated ovarian carcinosarcoma case material, including a BRCA-wildtype patient treated for more than 20 months; broader PARP inhibitor case series also reported maintenance use with progression-free survival ranging from 13 to 72 months. [6][86][43][123][107]5 sources
  • trastuzumab deruxtecan: Trastuzumab deruxtecan was reported in preclinical uterine and ovarian carcinosarcoma models and in case material; a small retrospective gynecologic series including two ovarian carcinosarcoma patients reported overall mixed outcomes, with partial response, stable disease, and progression in the full cohort. [9][195][196][123][43]5 sources
  • HER2-directed therapy · HER2-targeted therapy: HER2-directed therapies, trastuzumab, T-DM1, SYD985, and related antibody-drug conjugates were studied in carcinosarcoma models or discussed for HER2-overexpressed disease. [89][9]
  • elimusertib: Elimusertib was reported in preclinical ovarian and uterine carcinosarcoma models with in vitro sensitivity and in vivo antitumor activity, particularly in HRD tumors. [159]
  • vascular endothelial growth factor inhibitors: Vascular endothelial growth factor inhibitors were described in case reports with variable outcomes. [12]

Immunotherapy

  • WT1 mRNA-loaded dendritic cell immunotherapy: WT1 mRNA-loaded dendritic cell immunotherapy was reported as feasible without toxicity, but disease progression occurred after vaccination. [161]
Show 2 lab & early-research entries
  • pembrolizumab: Pembrolizumab was reported in ovarian carcinosarcoma case material, including a heavily pretreated metastatic case with an objective response and another case report describing encouraging outcomes after immunotherapy with emphasis on microsatellite instability testing. [4][48][59]3 sources
  • solitomab: Solitomab showed in vitro cytotoxic activity against EpCAM-positive carcinosarcoma cells. [29]

Repurposed drugs

  • cyclosporin A: Cyclosporin A with carboplatin was studied in a phase II trial in refractory ovarian and fallopian tube cancer, including one ovarian mixed mesodermal tumor, with reported response and thrombocytopenia. [197]

Procedures & devices

  • cytoreductive surgery: Cytoreductive surgery, debulking surgery, optimal cytoreduction, surgical resection, tumorectomy, surgery with arterial reconstruction, cardiopulmonary bypass with IVC tumor/thrombus resection, and other procedures were reported as part of management. [168][180][47][49][183][66][188][106][78][189][147][165][91][190]14 sources
  • hyperthermic intraperitoneal chemotherapy: Hyperthermic intraperitoneal chemotherapy after cytoreduction was reported in an advanced-stage ovarian carcinosarcoma cohort; HIPEC agents included carboplatin, cisplatin plus doxorubicin, and melphalan. [198][15][43][123]4 sources
  • cardiophrenic lymph node resection: Cardiophrenic lymph node resection was reported in a surgical series that included one ovarian carcinosarcoma case. [180]
  • synthetic arterial graft reconstruction: Individual case material reported synthetic arterial graft reconstruction and postoperative adhesions causing obstructive ileus after para-aortic lymph node dissection. [188][85]
  • lymphadenectomy: Lymphadenectomy was associated with improved overall survival in a meta-analysis, including a significant association in the carcinosarcoma subgroup. [101]
  • liver mobilization and the Pringle maneuver: Liver mobilization and the Pringle maneuver were used during cytoreductive surgery to achieve complete resection of a bulky subphrenic metastasis. [199]
  • bilateral prophylactic oophorectomy: BRCA1 or BRCA2 variantsIn a family-based study of 551 women with BRCA1 or BRCA2 variants, bilateral prophylactic oophorectomy was associated with a reduction in the risk of ovarian cancer reported as a relative risk of 0.04 (95% confidence interval, 0.01–0.16) with average follow-up of 9 years. [138]
    relative risk 0.04 (95% CI 0.01–0.16) vs no prophylactic surgery
    Source quote
    • “Prophylactic surgery was associated with a reduction in the risk of ovarian cancer that exceeded 90% (relative risk, 0.04; 95% confidence interval, 0.01–0.16), with an average follow-up of 9 years.”
  • secondary cytoreductive surgery (SCS): Among patients with recurrence, secondary cytoreductive surgery (SCS) was performed in 27 patients and 19 of those had no visible residual disease after SCS. [121]
    median PFS (PCS vs NACT/ICS) 26.4 vs 20 months, p = 0.049 vs NACT/ICSmedian OS (PCS vs NACT/ICS) 50.4 vs 17.1 months, p = 0.005 vs NACT/ICSproportion receiving platinum-based chemotherapy 98.8%proportion of platinum-treated patients receiving platinum+taxane 95.3%
    Source quotes
    • “The median PFSs were 26.4 and 20.0 months for the PCS group and the NACT/ICS group (P = 0.049), respectively.”
    • “Moreover, the median OS was 50.4 months for the PCS group compared with 17.1 months for those who received NACT/ICS (P = 0.005)”
    • “The vast majority (98.8%) of patients were treated with platinum-based regimens.”
    • “Of these, 81 patients (95.3%) received platinum and taxane combination therapy,”
  • tertiary debulking surgery: Tertiary debulking surgery was performed in 11 patients among those who developed a second recurrence. [121]
    median PFS (PCS vs NACT/ICS) 26.4 vs 20 months, p = 0.049 vs NACT/ICSmedian OS (PCS vs NACT/ICS) 50.4 vs 17.1 months, p = 0.005 vs NACT/ICSproportion receiving platinum-based chemotherapy 98.8%proportion of platinum-treated patients receiving platinum+taxane 95.3%
    Source quotes
    • “The median PFSs were 26.4 and 20.0 months for the PCS group and the NACT/ICS group (P = 0.049), respectively.”
    • “Moreover, the median OS was 50.4 months for the PCS group compared with 17.1 months for those who received NACT/ICS (P = 0.005)”
    • “The vast majority (98.8%) of patients were treated with platinum-based regimens.”
    • “Of these, 81 patients (95.3%) received platinum and taxane combination therapy,”
Show 1 lab & early-research entry
  • surgery: Emergency surgery with bilateral salpingo-oophorectomy, total hysterectomy, appendectomy, and small intestine adhesiolysis was reported in one patient with sepsis. [146]

Other

  • PLAP: PLAP immunostaining was detectable in a subset of ovarian carcinosarcomas in one tissue microarray study. [200]
  • ReACp53: The source describes ReACp53 being tested in cell-line mini-ring assays as one of three drugs evaluated at five concentrations in triplicates. [192]
  • Staurosporine: The source describes Staurosporine being tested in cell-line mini-ring assays as one of three drugs evaluated at five concentrations in triplicates. [192]
  • Flavopiridol: Flavopiridol was included in the organoid screening experiments as a positive control. [192]
  • BS-181 HCl: BS-181 HCl was included in the organoid screening experiments as a negative control. [192]
Staging & risk44 points
  • The sources state that OCS is often diagnosed at advanced stage. [6][8][9]3 sources
  • Sources describe ovarian carcinosarcoma as often presenting with advanced disease, and one source states that more than half of women are diagnosed at an advanced stage. [50][51][54]3 sources
  • FIGO stage is described as the strongest or most important prognostic factor. [61][64][62]3 sources
  • Ovarian carcinosarcoma is staged according to the FIGO staging of epithelial ovarian tumors, and one nomogram study reported that its nomograms performed better than staging and grading systems. [21][20]
  • The incidence of positive nodes at primary surgery has been reported to be as high as 24% in stage I, 50% in stage II, 74% in stage III, and 73% in stage IV ovarian epithelial cancer. [138]
  • Most tumors were FIGO stage III or IV in one ultrasound series. [90]
  • In one study, 14% of women with ovarian carcinosarcoma were diagnosed with localized disease. [201]
  • In one study, early diagnosis at stage I was associated with better overall survival. [115]
  • In one study, stage I/II disease had longer progression-free survival and overall survival than stage III/IV disease, although the progression-free survival difference was not statistically significant. [178]
  • One series reported 5-year survival rates of 71% for stage I/II, 42% for stage III, and 17% for stage IV disease. [81]
  • In one series, stage was associated with overall survival, with stage I having better survival than stages II, III, and IV. [87]
  • The ovarian carcinosarcoma nomogram study used AJCC stage as a prognostic factor in its model. [16]
  • The review states that comprehensive staging is the surgical goal in early-stage disease and optimal cytoreduction is the surgical goal in advanced-stage tumors. [27]
  • In one institutional series, the analyzed patients included stage I, II, III, and IV disease, with most advanced-stage cases being stage III or IV. [169]
  • In another series, 80% of patients presented with advanced FIGO stage III or IV disease. [37]
  • One source reports a case classified as advanced stage IIIB (FIGO 2014). [187]
  • One source reports a case of pathologically confirmed stage IVB ovarian carcinosarcoma with multiple solid nodules in both lungs. [49]
  • One source states that ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer. [59]
  • One review states that the staging system for ovarian and primary peritoneal cancer is also used for MMMT. [68]
  • One report described a unique stage IV complex ovarian carcinosarcoma. [153]
  • Another report described a stage III-C malignant mixed Mullerian tumor. [74]
  • One source reports FIGO stage III disease in two long-term survivors. [190]
  • Another source states that these tumors are usually in advanced stages when diagnosed. [91]
  • One source reports FIGO IIIC left ovarian carcinosarcoma. [199]
  • In a series of gynecologic mesonephric-like carcinosarcomas (MLCS), patients presented across FIGO stages I–IV (I:3, II:2, III:2, IV:1). [136]
  • In one retrospective series, 22.6% of patients were stage IC-II, 67.7% were stage III, and 9.7% were stage IV at diagnosis. [2]
  • The 2006 retrospective series reported FIGO stage IIC, IIIC, and IV disease among ten patients. [179]
  • The Korean registry study reported localized, regional, and distant stage categories, and patients with localized stage had better survival than those with regional or distant stage. [110]
  • Patients in the cited cohort were classified according to the FIGO classification. [26]
  • In one cohort, 18.1% of cases were early stage I or II and 81.8% were advanced stage III or IV. [26]
  • In one SEER analysis, the majority of women with OMMMT had advanced-stage disease at diagnosis. [202]
  • In the 90-patient cohort, FIGO stage distribution was 6.7% stage I, 12.2% stage II, 58.9% stage III, and 22.2% stage IV. [121]
Show 12 lab & early-research findings
  • One source reports an advanced stage IIIc ovarian carcinosarcoma cell line. [139]
  • The sources report peritoneal involvement and lymph node metastases, and one case report describes cutaneous metastasis. [50][52]
  • Some reported cases described peritoneal fluid involvement, including positive peritoneal fluid cytology; one imaging series also reported ascites in all patients. [50][54]
  • One case report assigned the tumor to FIGO stage IIIc. [55][84]
  • One source reports a case of stage IIIC ovarian carcinosarcoma; another case report describes paraaortic lymph node metastases as the only extrapelvic dissemination but does not state surgical stage IIIA1 in the provided text. [85][128]
  • In one 27-case series, 14 patients had advanced stage disease at presentation. [32]
  • In one case report, ovarian carcinosarcoma metastasized to the spleen as a solitary splenic metastasis. [122]
  • In one case series, the stage distribution was 1 stage I, 6 stage II, 23 stage III, and 1 stage IV. [171]
  • One case report states that the final diagnosis was ovarian carcinosarcoma with squamous cell carcinoma in the carcinomatous component, stage IIIA1. [56]
  • One case report described stage III disease. [62]
  • The imaging review reported FIGO stage IIIb and IV in one patient each and stage IIIc in six patients. [165]
  • One case report assessed the patient as having stage IV disease. [203]
Prognosis93 points
  • Ovarian carcinosarcoma has been described as having a poor prognosis. [204][5][6][82][8][9][4][10][83][47][164][73][74][67][129][59][48][42][45][30][34][85][55][107][113]25 sources
  • One review states that the median overall survival for ovarian carcinosarcoma is less than two years. [15][16][59][48][42][67][129]7 sources
  • Sources describe ovarian carcinosarcoma as having a very poor or extremely poor prognosis. [164][53][52][55][107][113]6 sources
  • One review states that advanced stage is associated with worse survival in ovarian carcinosarcoma. [15][38][30][118]4 sources
  • One review states that most available retrospective studies support cytoreductive surgery in OCS, with optimal debulking associated with improved survival. [6][27]
  • In one retrospective series, older age, advanced stage, and residual disease greater than 1 cm after primary cytoreductive surgery were independently associated with worse survival. [170][37]
  • In the cohort, the median progression-free survival (PFS) was 26.0 months (95% CI: 20.6–31.4). [121]
  • In the cohort, the median overall survival (OS) was 48.0 months (95% CI: 25.4–70.6). [121]
  • The authors concluded that primary ovarian sarcoma has a poor overall prognosis. [99]
  • In the series, the median survival for the entire group was 18.7 months, with a one-year survival rate of 58% and a two-year survival rate of 29%. [99]
  • The systematic review states that heterologous sarcoma component did not shorten life expectancy. [1]
  • In one retrospective study, ascites and platinum resistance were independent risk factors for decreased overall survival. [172]
  • In one case-control study, median disease-free survival was 29 months for ovarian carcinosarcoma and 27 months for ovarian high-grade serous carcinoma. [172]
  • In one database study, the five-year survival rate was 26.63% for ovarian carcinosarcoma and 43.61% for high-grade papillary serous ovarian carcinoma. [204]
  • One study reported that age over 65 years, tumor extension, and platinum-based chemotherapy were independent predictors of survival; in multivariate analysis, age, tumor extension, and uterine versus ovarian carcinosarcoma were independent predictors of overall survival. [201]
  • In one study, bilateral ovarian tumors and metastatic tumors larger than 2 cm were associated with poorer overall survival. [115]
  • In one study, the median overall survival was 19.7 months for the entire cohort. [2]
  • The 2026 organoid study describes ovarian carcinosarcoma as a rare and aggressive tumour type with limited treatment options and poor responses to standard platinum therapy. [4]
  • The 2006 retrospective series reported overall survival rates of 60.0% at 1 year, 40.0% at 2 years, and 20.0% at 5 years. [179]
  • The 2004 GOG cisplatin study reported that 57% of evaluable patients had increasing disease. [177]
  • One retrospective study found that tumor stage, comorbidities, and chemotherapy were associated with overall survival. [87]
  • One retrospective study found that no chemotherapy was associated with worse overall survival than chemotherapy, and that higher comorbidity burden was associated with worse overall survival. [87]
  • The scoping review states that prognosis remains poor even when the tumor is localized in the ovary, and that the median survival rate is lower than 2 years. [10]
  • In the Korean registry study, the median overall survival was 39 months and the 5-year overall survival rate was 42.5%. [110]
  • In one study, late-stage ovarian carcinosarcoma was among the histotypes with the poorest survival. [11]
  • One SEER-based review states that ovarian carcinosarcoma had the lowest 5-year survival rate among gynecologic carcinosarcomas studied. [13]
  • In the nomogram study, age, grade, tumor size, AJCC stage, surgery, and chemotherapy were independent prognostic factors for overall survival. [16]
  • In the CRS/HIPEC cohort, median progression-free survival was 11.7 months and median overall survival was 21.3 months. [198]
  • A SEER analysis reported that lymphadenectomy was associated with better overall survival in AJCC T2 early ovarian carcinosarcoma, but not in AJCC T1 disease. [24]
  • In one cohort, homologous sarcomatous subtype was associated with better disease-free survival and overall survival than heterologous subtype, and residual disease after surgery was associated with poorer disease-free survival and overall survival. [26]
  • One comparative study reported 5-year disease-free survival of 19% for ovarian carcinosarcoma and 54% 5-year overall survival. [117]
  • In one institutional series of advanced-stage ovarian carcinosarcoma, the median progression-free survival was 10 months and the median overall survival was 21 months. [169]
  • Prognosis for localized stage disease is poor, with a high risk of local and distant recurrences occurring within 1 year. [30]
  • The survival of women with advanced uterine or ovarian carcinosarcoma is worse than the survival of women with endometrioid or high-grade serous histologies. [30]
  • No improvement in survival rates has been observed in the past few decades, and overall median survival is reported as less than 2 years. [30]
  • Advanced stage, suboptimal cytoreduction, and sarcoma predominant tumors are likely to have a worse outcome in ovarian MMMT. [32]
  • In one series, recurrence-free survival was 10.5 months in advanced stage disease compared with 13 months in early stage disease and epithelial predominant tumors. [32]
  • One review states that the tumor is associated with an average survival of less than 2 years. [34]
  • Median survival was 38 months in one retrospective cohort of 22 patients. [111]
  • Median survival was 46 months for optimally debulked patients and 27 months for suboptimally debulked patients in one retrospective cohort. [111]
  • In one comparison study, the median survival for ovarian carcinosarcoma was 11 months and the hazard ratio for overall survival versus uterine carcinosarcoma was 0.991. [112]
  • Median survival for the entire group was 21 months in one 31-patient series. [171]
  • Median overall survival was 32.9 months in one nine-patient institutional series. [132]
  • Median cause-specific survival was 8.2 months in one prospective series of carcinosarcoma and serous adenocarcinoma comparison, and median progression-free survival was 6.4 months in one prospective series. [184]
  • Residual disease after surgery was associated with decreased overall survival in stage IIIC disease in one series. [171]
  • One series reported an overall 5-year survival rate of 27.1%. [38]
  • In that series, 5-year survival was 100% for stage I, 31.3% for stage II, 10.9% for stage III, and 0% for stage IV. [38]
  • Low-stage disease, defined as stages I and II, was a significant prognostic factor for survival in one study. [38]
  • One series reported an overall median survival of 247 days, with 40% 1-year survival and 6% 5-year survival. [39]
  • In one retrospective series, stage III or IV disease had a median survival of 18 months and a 5-year survival rate of 8%. [173]
  • Advanced stage appears to be a poor prognostic indicator of survival. [38]
  • Histology, including homologous or heterologous subtype and the grade, type, or percentage of the epithelial component, had no significant impact on survival in one series. [39]
  • One source states that ovarian carcinosarcoma has a poor prognosis. [47]
  • One source states that fistulization to the large intestine worsens prognosis. [47]
  • OCS is described as an aggressive tumour with a dismal prognosis. [85]
  • One review states that patients are usually given a poor prognosis of under three years. [67]
  • Stage of disease is described as the most important predictor for survival. [70]
  • One review states that heterologous elements have no prognostic effect. [70]
  • One review states that the predominance of the stromal component aggravates the prognosis. [68]
  • Ovarian malignant mixed müllerian tumors usually yield poor outcomes. [73]
  • These tumors have a generally poor prognosis and often develop recurrent disease. [74]
  • One report describes two patients who were disease-free 2 and 3 years after initial therapy. [166]
  • One source reported that a patient died from disease 17 months after surgery. [84]
  • The same report described another 22-month progression-free survival after liposomal doxorubicin and later liposomal doxorubicin/carboplatin, without obvious toxicity. [75]
  • One source states that patients with ovarian malignant mixed müllerian tumor have a median survival of 18 months and a 5-year survival rate of 8%. [75]
  • Long-term survival is described as unusual in ovarian malignant mixed mullerian tumor. [190]
  • One review reports that 77.6% of patients were dead of their disease within 1 year. [91]
  • Limited data suggest that patients treated with surgery and combination chemotherapy survive longer. [91]
  • Two stage III patients in one report had prolonged survival after surgery plus adjuvant therapy, but the report presents these as unusual examples rather than typical outcomes. [190]
  • One review states that ovarian carcinosarcoma had survival similar to neuroendocrine carcinoma of the ovary. [97]
  • The same analysis concluded that race was not an independent prognostic factor in ovarian carcinosarcoma. [100]
  • One source reports a median duration of response of 13 months in four complete responders. [96]
  • One source reports that overall survival was poor, with a median survival of 16+ months in all 10 patients. [96]
  • Multivariate analyses identify several factors reported as the most important favorable prognostic factors for ovarian cancer, including younger age, good performance status, non-mucinous/clear-cell cell type, well-differentiated tumor, early-stage disease, absence of ascites, lower disease volume before debulking, smaller residual tumor after cytoreductive surgery, and BRCA1 or BRCA2 variant. [138]
  • Recent reviews and cohort studies describe ovarian carcinosarcoma as having poor survival outcomes. [11][12]
  • Disease recurrence was observed in 52 patients (57.8%) in the cohort. [121]
  • The Korean registry study reported worse survival for distant stage disease than for localized or regional stage disease. [110]
  • In the Scottish cohort, multivariable analysis found ovarian carcinosarcoma associated with poorer outcome than high-grade serous, endometrioid, mucinous, and low-grade serous ovarian carcinoma. [11]
  • In the Scottish cohort, there was no significant difference in survival between clear cell ovarian carcinoma and ovarian carcinosarcoma in multivariable analysis. [11]
  • In the SEER-based review, the 5-year cause-specific survival rate for ovarian carcinosarcoma was 25.8%. [13]
  • The same SEER analysis reported no statistically significant survival difference for lymphadenectomy in AJCC T1 disease. [24]
  • The same SEER analysis reported that lymph node metastasis was associated with worse survival in AJCC T2 disease. [24]
  • One SEER study reported that survival for both early- and late-stage ovarian carcinosarcoma was inferior to serous tumors. [31]
  • In a case-control study, advanced ovarian carcinosarcoma had worse response and survival than serous epithelial ovarian cancer. [164]
  • In a SEER analysis, ovarian carcinosarcoma prognosis was influenced by age, stage, and lymphadenectomy. [118]
  • Advanced-stage OMMMT had a higher risk of death than advanced-stage high-grade epithelial ovarian cancer in one SEER analysis, and ovarian carcinosarcoma had a significantly worse prognosis than epithelial ovarian cancer in one SEER analysis. [202]
  • One retrospective series reported that one patient died from recurrence and metastasis, while three patients were alive without obvious recurrence or metastasis during follow-up of 9 to 59 months. [57]
  • The population-based analysis reported a risk of death of 1.19 for non-Hispanic Black versus non-Hispanic White patients with ovarian carcinosarcoma after adjustment for demographic factors, which became insignificant after adjustment for comorbidity. [100]
Show 5 lab & early-research findings
  • One case report described a patient who was followed for six years after surgery and chemotherapy and was in good health; the authors noted long-term disease-free survival. [55]
  • One case report describes a patient who died of disease 3 years 10 months after initial treatment. [71]
  • A case report described no new metastatic lesions on CT scan three months after palliative chemotherapy. [74]
  • A case report described 41 months of remission after aggressive surgical debulking, platinum-containing chemotherapy, and intraoperative radiotherapy. [75]
  • A case report review states that ovarian carcinosarcomas occurring in endometriotic cysts are particularly rare and may have a relatively good prognosis. [102]
Safety & interactions21 points
  • The Cochrane review found no trials, so no safety or efficacy data were analyzed. [80]
  • In the phase III trial, toxicities were similar between paclitaxel-carboplatin and paclitaxel-ifosfamide, except for more hematologic toxicity with paclitaxel-carboplatin and more confusion and genitourinary hemorrhage with paclitaxel-ifosfamide. [175]
  • The phase II study reported that adverse events were comparable across study arms for intermittent relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy. [205]
  • Trabectedin was associated with grade 3-5 neutrophil count decreases and transaminase increases in the phase II trial. [191]
  • In one study, two women did not complete treatment because of rapid disease progression and severe toxicity. [178]
  • The same study states that the combination of anthracycline, alkylating agent, and cisplatin showed a good response rate but also a high toxicity. [178]
  • In the cisplatin study, grade 2 or higher adverse effects included nausea and vomiting, leukopenia, neutropenia, thrombocytopenia, anemia, azotemia, neurotoxicity, fever, and tinnitus. [177]
  • In the cyclosporin A and carboplatin study, the most common grade 3 or 4 toxicity was thrombocytopenia in 22% of patients, and hypertension occurred in 18% during infusion. [197]
  • In the CNTO 95 phase I study, infusion-related fever occurred in one grade III and four grade II episodes among 24 enrolled patients. [193]
  • WT1 mRNA-loaded dendritic cell vaccination was feasible without toxicity in one report. [161]
  • One report of o,p'-DDD therapy described side effects including low T4, increased bleeding time, increased substitution requirements for hydrocortisone and fludrocortisone acetate, and periods of hypoadrenocorticism with prerenal uraemia, and the same report states that a reduced mineralocorticoid activity induced by o,p'-DDD was reversed after discontinuation of treatment. [206]
  • One source reports no severe intraoperative or postoperative complications after subphrenic tumor resection using liver mobilization and the Pringle maneuver. [199]
  • One source reports that the patient suffered from cachexia and sepsis during the course of treatment. [146]
  • One source reports that the patient required emergency surgery owing to sepsis. [146]
  • In the caspase 3/7 cleavage assay reported by the authors, doxorubicin was omitted because its fluorescence overlapped with the caspase signal. [192]
  • In the CRS/HIPEC cohort, major complications occurred in 25% of patients, there was no 90-day mortality, and malignant bowel obstruction occurred in 18.7% of patients. [198]
Show 5 lab & early-research findings
  • One case report of non-islet cell tumor hypoglycemia in ovarian carcinosarcoma describes treatment with prednisone, continuous dextrose, and glucagon infusion. [46]
  • One case report described surgical management of ovarian carcinosarcoma with IVC and right atrial extension and noted challenges related to coagulopathy. [106]
  • One case report described postoperative obstructive ileus caused by adhesion between the abdominal aorta and terminal ileum after surgery. [85]
  • One recurrent case report stated that liposomal doxorubicin and later liposomal doxorubicin/carboplatin were given without obvious toxicity. [75]
  • Another case report described acute hepatitis caused by reactivation of hepatitis B virus infection during chemotherapy with adriamycin and cisplatin, and the patient died of hepatic failure two weeks later. [147]
What we don't know yet25 points
  • Reported chemotherapy regimens have shown mixed results, and the preferred first-line or adjuvant regimen remains unknown. [80][2][26][160][31][34][122][37][40][167][85][68][61][64][24][25][23][22][124]19 sources
  • Several sources describe ovarian carcinosarcoma treatment as uncertain or not yet determined, with limited evidence and no unified treatment plan. [13][22][23][24][25][16][55][107][113][85][56][59][68][34][40][122][37][49][47]19 sources
  • Sources state that ovarian carcinosarcoma is rare, high-quality evidence is limited, and future prospective studies and clinical trials are needed. [6][22][89][65][60][37][21][15][85][59][51][50]12 sources
  • Sources describe the role of radiotherapy in ovarian carcinosarcoma as needing further study. [37][113][64][10]4 sources
  • Sources describe ovarian carcinosarcoma prognostic assessment as limited or insufficient, and report proposed prognostic factors that require further study. [86][16][91][43]4 sources
  • Randomized or well-designed non-randomized studies are still needed to compare treatment modalities and improve current knowledge. [80][39][65]3 sources
  • The effect of chemotherapy on the different components of ovarian carcinosarcoma is largely unknown, and further studies are required to define the value of intraperitoneal chemotherapy. [185][166]
  • A 2024 study describes OCS as understudied and investigates molecular events that may drive sarcomatous compartment formation through EMT, including global differences in microRNA profiles between compartments. [8]
  • No pathognomonic ultrasound sign of ovarian carcinosarcoma was found. [90]
  • The 2023 phase II study reported that the primary end point did not meet statistical significance after multiplicity adjustment. [205]
  • A 2026 organoid study describes ovarian carcinosarcoma as a rare, aggressive tumour type with limited treatment options and poor responses to standard platinum therapy. [4]
  • A recent study notes that ovarian carcinosarcoma has been excluded from many pan-histotype ovarian carcinoma studies, limiting understanding of its behavior. [11]
  • One review says the role of radiotherapy and novel therapies needs further study. [10]
  • The role of lymphadenectomy in early-stage ovarian cancer remains under study. [101]
  • Substantial knowledge gaps remain for rare histotypes. [104]
  • Racial disparities in characteristics, treatment, and survival in ovarian carcinosarcoma merit additional research. [100]
  • The net clinical benefit of serial CA-125 monitoring of patients undergoing treatment for recurrence has not been determined. [138]
  • There is little guidance about patient follow-up after initial induction therapy for ovarian epithelial cancer. [138]
  • Peritoneal malignant mesothelioma (PMM) can present with symptoms similar to primary ovarian carcinoma (for example, dyspepsia, abdominal discomfort from ascites, and a palpable abdominal mass); PMM most commonly shows diffuse spread of peritoneal lesions without a dominating tumor mass whereas primary ovarian tumors more often present with a large pelvic mass and smaller extra-ovarian metastatic lesions; and both PMM and primary ovarian tumors frequently cause fibrosis and adhesion that can prevent clear identification of tumor origin intraoperatively. [207]
  • Histopathologic diagnosis can be difficult because PMM may be biphasic (epithelial and sarcomatous components) or monophasic of either type; when only the epithelial component is present, serous ovarian carcinoma is an important differential diagnosis, and biphasic mesothelioma must be differentiated from malignant mesodermal mixed tumor or carcinosarcoma of the ovary; pathologists generally require immunohistochemical study to achieve a correct diagnosis between these entities. [207]
  • The 2026 retrospective cohort study described its findings as exploratory and hypothesis-generating. [176]
  • Reviews and case-based reports describe limited prospective evidence for targeted therapies in ovarian carcinosarcoma; PARP inhibitors are discussed mainly as a rationale or in small case reports/series, including some BRCA-mutated and HRD-positive cases. [6][92][208][107]4 sources
  • Case reports suggest a possible relationship between STIC and ovarian carcinosarcoma, but this relationship remains uncertain. [28][42]
  • One case report concludes that further cases need to be accumulated to determine a successful treatment modality. [71]
  • Neuroectodermal differentiation in ovarian MMMTs is exceedingly uncommon, with only a few case reports in the literature. [72]

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked September 8, 2026.

  1. Systematic reviewThe clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review · 2022
  2. Clinical trialComparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature · 2018
  3. Review articleEndometriosis-Associated Ovarian Carcinosarcoma Featuring Well-Differentiated Adenocarcinoma and Fetal Rhabdomyoma-Like Mesenchymal Components: An Unusual Case Report-With Molecular Analysis · 2026
  4. Review articleHigh-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma · 2026
  5. Review articleMRI Findings of Ovarian Carcinosarcoma: A Retrospective Comparison With Endometrioid Carcinoma · 2026
  6. Review articleRecent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report · 2025
  7. Review articleGenomics of ovarian cancers and the potential of precision medicine · 2025
  8. Review articleCompartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma · 2024
  9. Review articleMesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression · 2024
  10. Review articleSpotlight on Carcinosarcoma of the Ovary: A Scoping Review · 2024
  11. StudyOvarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes · 2024
  12. Review articleGenomic and Molecular Characteristics of Ovarian Carcinosarcoma · 2023
  13. Review articleTrends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database · 2023
  14. StudyGermline drivers of gynecologic carcinosarcomas · 2023
  15. Review articleFrontiers of Ovarian Carcinosarcoma · 2023
  16. Review articleEstablishment and validation of a novel nomogram for survival prediction of ovarian carcinosarcoma · 2022
  17. Review articleOvarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma · 2022
  18. Review articleEpithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin · 2022
  19. Review articleTherapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid · 2021
  20. Review articleClinical Nomograms for Predicting the Overall Survival and Cancer-specific Survival of patients with Ovarian Carcinosarcoma patients after Primary Surgery · 2021
  21. Review articleDetailed overview on rare malignant ovarian tumors · 2020
  22. Review articleOverall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience · 2019
  23. Review articleOvarian carcinosarcoma: Current developments and future perspectives · 2019
  24. Review articlePrognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma · 2018
  25. Review articleClinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma · 2017
  26. Review articlePrognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma · 2017
  27. Review article"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities" · 2016
  28. Review articleOvarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma · 2016
  29. Review articleSolitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro · 2015
  30. Review articleGynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma · 2014
  31. Review articleCarcinosarcoma of the ovary: natural history, patterns of treatment, and outcome · 2013
  32. Review articleClinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases · 2013
  33. Review articleCarcinosarcoma of the ovary: a review of the literature · 2012
  34. Review articleCarcinosarcoma of the ovary a review · 2009
  35. Review articleCurrent management of ovarian carcinosarcoma · 2007
  36. Review articleCarcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience · 2007
  37. StudyCarcinosarcoma of the ovary · 2003
  38. Review articlePrognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases · 2000
  39. Review articleCarcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients · 1995
  40. Review articleCarcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital · 1994
  41. Case reportStage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission · 2026
  42. Case reportThe development of ovarian carcinosarcoma from serous tubal intraepithelial carcinoma: an immunohistochemical case report with literature review · 2026
  43. Case reportThe use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series · 2025
  44. Case reportBilateral ovarian carcinosarcoma - A rare and aggressive malignancy: Case report · 2025
  45. Case reportOvarian Carcinosarcoma Mimicking Symptoms of Recurrent Diverticulitis: A Case Report · 2024
  46. Case reportInitial Presentation of Ovarian Carcinosarcoma With Non-islet Cell Tumor Hypoglycemia: A Case Report · 2024
  47. Case reportSigmoido-ovarian fistula complicating ovarian carcinosarcoma: a case report · 2024
  48. Case reportOvarian Carcinosarcoma and Response to Immunotherapy · 2023
  49. Case reportOvarian carcinosarcoma with lung metastasis characterized by persistent fever: A case report and literature review · 2024
  50. Case reportCarcinosarcoma of the ovary: a case report and literature review · 2023
  51. Case reportMetastatic ovarian carcinosarcoma in a patient undergoing in-vitro fertilization: A case report · 2023
  52. Case reportCutaneous metastasis of carcinomatous component of ovarian carcinosarcoma: A case report and review of the literature · 2022
  53. Case reportDo Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma · 2022
  54. Case reportPrimary ovarian malignant mixed Müllerian tumor: a rare case report · 2022
  55. Case reportGenetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review · 2022
  56. Case reportA rare case of ovarian carcinosarcoma with squamous cell carcinoma · 2019
  57. Case reportPrimitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases · 2020
  58. Case reportOvarian Teratoid Carcinosarcoma Is an Aggressive Tumor of Probable Mullerian Derivation with a Carcinosarcomatous and Mixed Germ-Cell Morphology · 2019
  59. Case reportResponse to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma · 2018
  60. Case reportCauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread · 2019
  61. Case reportPrimary Ovarian Malignant Mixed Mullerian Tumour: A Case Report and Brief Review of Literature · 2016
  62. Case reportProlonged survival of a patient with pelvic recurrence of ovarian malignant mixed mullerian tumor after chemoradiotherapy · 2014
  63. Case reportMature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report · 2016
  64. Case reportThe Use of Lattice Radiation Therapy (LRT) in the Treatment of Bulky Tumors: A Case Report of a Large Metastatic Mixed Mullerian Ovarian Tumor · 2015
  65. Case reportOvarian carcinosarcoma: a case report, diagnosis, treatment and literature review · 2015
  66. Case reportOvarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor · 2014
  67. Case reportCarcinosarcoma of the ovary: case report and literature review · 2012
  68. Case reportMalignant mixed Mullerian tumor of the ovary with two cases and review of the literature · 2011
  69. Case reportA case of bilateral ovarian synchronous tumors (left ovarian serous papillary adenocarcinoma and right ovarian malignant mixed Müllerian tumor) · 2011
  70. Case reportOvarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: case report with review of the literature · 2011
  71. Case reportMalignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings · 2010
  72. Case reportOvarian malignant mixed mesodermal tumor with neuroectodermal differentiation: a multifaceted evaluation · 2010
  73. Case reportPrimary malignant mixed müllerian tumor of the ovary · 2010
  74. Case reportPancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy · 2006
  75. Case reportExcellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review · 2004
  76. Case reportCarcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin · 2000
  77. Case reportMR images of ovarian carcinosarcoma · 1999
  78. Case reportTeratoid carcinosarcoma of the ovary with prominent neuroectodermal differentiation · 2001
  79. Case reportComplete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine · 1991
  80. Systematic reviewChemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma · 2013
  81. Review articleClinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas With an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors · 2026
  82. Review articleLoss of SMARCA4 induces sarcomatogenesis through epithelial-mesenchymal transition in ovarian carcinosarcoma · 2025
  83. Review articleT-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review · 2021
  84. Case reportPrimary ovarian carcinosarcoma: a case report and review of the literature · 2004
  85. Case reportOvarian Carcinosarcoma with Retroperitoneal Para-Aortic Lymph Node Dissemination Followed by an Unusual Postoperative Complication: A Case Report with a Brief Literature Review · 2020
  86. StudyReal-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China · 2025
  87. Review articleThe impact of demographic, clinical, and treatment factors on overall survival in ovarian carcinosarcomas: a National Cancer Database study · 2025
  88. StudyManagement of a rare ovarian carcinosarcoma: A case report and literature review · 2022
  89. Review articleSYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression · 2017
  90. Clinical trialImaging in gynecological disease (23): clinical and ultrasound characteristics of ovarian carcinosarcoma · 2022
  91. Case reportMalignant mixed mesodermal tumors and carcinosarcoma of the ovary: report of eight cases and review of literature · 1983
  92. Review articleOvarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes · 2024
  93. Review articleTherapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network · 2022
  94. ObservationalRadical surgical cytoreduction in the treatment of ovarian carcinosarcoma · 2014
  95. Clinical trialDifferential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression · 2012
  96. Review articlePlatinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary · 1989
  97. Clinical trialClinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary · 2020
  98. Case reportParaneoplastic cerebellar degeneration secondary to ovarian carcinosarcoma: a cerebellar conundrum · 2017
  99. StudyPrimary sarcoma of the ovary: clinicopathological characteristics, prognostic factors and evaluation of therapy · 2011
  100. Review articleRacial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival · 2020
  101. Systematic reviewImpact of Lymphadenectomy on Outcomes of Early-Stage Ovarian Cancer: A Systematic Review and Meta-Analysis · 2021
  102. Review articleOvarian carcinosarcoma of heterologous type occurring in an endometriotic cyst with 3-year recurrence-free survival: a case report and literature review · 2024
  103. Review articlePerspectives on Ovarian Cancer 1809 to 2022 and Beyond · 2022
  104. Review articleMolecular characteristics and clinical behaviour of epithelial ovarian cancers · 2023
  105. Review articlePresence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid · 2015
  106. Case reportSurgical management of ovarian carcinosarcoma with inferior vena cava extension into the right atrium · 2020
  107. Case reportCase Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma · 2021
  108. Case reportMultiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis · 2018
  109. Case reportCarcinosarcoma of ovary with its various immunohistochemical expression: Report of a rare case · 2015
  110. StudyIncidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea · 2024
  111. StudyCarcinosarcoma of the ovary · 2008
  112. Review articleClinical features and outcomes of uterine and ovarian carcinosarcoma · 2006
  113. Case reportOvarian malignant mixed Müllerian tumor: a rare case report from Tanzania · 2020
  114. Case reportCarcinosarcoma of Uterus and Ovary-Clinical, Morphological, and Immunohistochemical Study of Case Series · 2025
  115. Clinical trialPrimary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study · 2014
  116. Case reportMalignant mixed müllerian tumors of the ovary · 2000
  117. Review articleUterine and Ovarian Carcinosarcomas: Do They Behave Similarly? · 2017
  118. Review articleOvarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes · 2010
  119. Review articleCarcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis · 2013
  120. Review articleAvoiding sparse data bias: an example from gynecologic oncology · 2012
  121. Review articleClinical Characteristics and Treatment Outcomes in Ovarian Carcinosarcoma: A Retrospective Cohort Study of 90 Cases · 2026
  122. Review articleSolitary splenic metastasis from ovarian carcinosarcoma: a case report · 2011
  123. Case reportResponse of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report · 2023
  124. Review articlePlatinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis · 2025
  125. StudySingle-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma · 2024
  126. StudyMolecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations · 2024
  127. Review articleUnveiling the mille-feuille sign: a key to diagnosing ovarian carcinosarcoma in addition to ovarian metastasis from colorectal carcinoma on MRI · 2024
  128. Case reportCharacterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling · 2020
  129. Case reportNon-islet cell tumor hypoglycemia associated with recurrent carcinosarcoma of the ovary · 2013
  130. Case reportBilateral ovarian malignant mixed Mullerian tumor in a dog · 2009
  131. Case reportMixed mesodermal tumor of the ovary: immunohistochemical study with histogenetic consideration · 1993
  132. Review articleClinicopathological features of ovarian carcinosarcomas: a single institution experience · 2005
  133. Review articleEstradiol and progesterone receptors in gynecologic sarcomas · 1984
  134. Review articleOvarian malignant mixed mesodermal tumor: the occurrence of hyaline droplets containing alpha 1-antitrypsin · 1982
  135. Case reportCarcinosarcoma of the Ovary Arising in the Background of a Mucinous Neoplasm Distinct From a Mural Nodule · 2026
  136. StudyClinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous Component · 2025
  137. StudySTK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours · 2024
  138. GuidelinePDQ(R) Ovarian Epithelial, Fallopian, & Peritoneal Cancer Treatment — National Cancer Institute · n.d.
    Source: PDQ(R) Adult Treatment Editorial Board. PDQ Cancer Information Summaries. Bethesda, MD: National Cancer Institute. The NCI does not endorse this site or its content.
  139. Review articleEstablishment and characterization of the NEYS cell line derived from carcinosarcoma of human ovary with special reference to the susceptibility test of anticancer drugs · 2009
  140. Review articleDevelopment and characterization of a human cell line from an ovarian mixed Müllerian tumor (carcinosarcoma) · 1988
  141. Review articleKRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice · 2017
  142. Case reportOvarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube · 2019
  143. Case reportOvarian carcinoma recurring as carcinosarcoma · 2001
  144. Case reportOvarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report · 2013
  145. Case reportMalignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature · 2011
  146. Case reportA case of ovarian carcinosarcoma with a germline pathogenic variant of BRCA2 involving a perforated appendix with an abscess · 2023
  147. Case reportCarcinosarcoma of ovary associated with previous radiotherapy · 2001
  148. Clinical trialCarcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma · 2021
  149. Review articleMutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition · 2016
  150. Review articleExpression of adhesion molecules and the proliferative activity of carcinosarcoma of the ovary · 2014
  151. Review articleExtravascular migratory metastasis in gynaecological carcinosarcoma · 2014
  152. Review articleTransition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis · 2003
  153. Case reportMalignant Müllerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma) · 2008
  154. Case reportA case of malignant mixed mesodermal tumor (MMMT) of the ovary: MR features before and after chemotherapy · 1999
  155. Case reportMalignant mixed müllerian tumor of the ovary with prominent neuroectodermal differentiation (teratoid carcinosarcoma) · 1990
  156. Case reportMultiple malignancies (squamous cell carcinoma and sarcoma) arising in a dermoid cyst of the ovary · 1981
  157. Case reportMesonephric-Like Carcinosarcoma of the Ovary Associated with Low-Grade Serous Carcinoma: A Case Report · 2021
  158. Review articleGenome-wide spatial expression profiling in formalin-fixed tissues · 2021
  159. Review articleOvarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor · 2023
  160. Review articleConventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft · 2015
  161. Review articleImmunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma · 2013
  162. Case reportExtremely Locally Advanced Ovarian Malignant Mixed Mullerian Tumor in 37-Years-Old Female · 2017
  163. Case reportPrimary ovarian malignant mixed mesodermal tumor: report of four cases · 2014
  164. StudyCarcinosarcoma of the ovary: a case-control study · 2011
  165. Case reportMalignant mixed müllerian tumor of the ovary: imaging findings · 2001
  166. Case reportComplete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases · 2006
  167. Review articleShould MMMT still be treated with adjuvant taxane-based combination chemotherapy? · 2020
  168. Review articleIntraoperative Radiation Therapy for Gynecologic Malignancies: When Is It Indicated? · 2025
  169. Review articleCarcinosarcoma of the ovary: a single institution experience and review of the literature · 2016
  170. Review articleOvarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival · 2013
  171. Review articleCarcinosarcoma of the ovary-a case series · 2006
  172. Clinical trialCarcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment · 2018
  173. Review articleMalignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy · 1995
  174. Case reportPeritoneal cytology of uncommon ovarian tumors · 1992
  175. Randomized trialRandomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial · 2022
  176. Clinical trialAssociation of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study · 2026
  177. Clinical trialCisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study · 2004
  178. Clinical trialPlatinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma · 2009
  179. Clinical trialMalignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy · 2006
  180. Review articleCardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study · 2019
  181. Review articleRhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma · 2014
  182. Review articleComplete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET · 2012
  183. Review articleCarcinosarcoma of the ovary: analysis of 13 cases and review of the literature · 2011
  184. Review articleCarcinosarcoma of the ovary: 19 years of prospective data from a single center · 2004
  185. Review articleThe effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract · 1994
  186. Review articleProlonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report · 1998
  187. Case reportA case of ovarian carcinosarcoma with germline BRCA2 pathogenic variant · 2024
  188. Case reportAggressive Resection of Malignant Paraaortic and Pelvic Tumors Accompanied by Arterial Reconstruction with Synthetic Arterial Graft · 2021
  189. Case reportWhole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma · 2011
  190. Case reportMalignant mixed mullerian tumors of the ovary. An analysis of two long-term survivors · 1993
  191. Clinical trialEfficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) · 2022
  192. Review articleA simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids · 2019
  193. Clinical trialPhase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors · 2007
  194. Review articleFolate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma · 2023
  195. StudyReal-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies · 2024
  196. Review articleTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression · 2023
  197. Clinical trialModulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study · 1996
  198. Review articleOutcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma · 2023
  199. Case reportResection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver · 2018
  200. Clinical trialPattern of placental alkaline phosphatase (PLAP) expression in human tumors: a tissue microarray study on 12,381 tumors · 2021
  201. Clinical trialPrognostic determinants in patients with uterine and ovarian carcinosarcoma · 2013
  202. Review articleSurvival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT) · 2004
  203. Case reportBorderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma · 2001
  204. Clinical trialPatterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis · 2016
  205. Randomized trialRelacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study · 2023
  206. Case reportA case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications · 1992
  207. Case reportHuge peritoneal malignant mesothelioma mimicking primary ovarian carcinoma · 2013
  208. Case reportSuccessful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report · 2024

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
1
Meta-analysis
0
Systematic review
3
Randomized trial
2
Clinical trial
17
Observational
1
Case report
85
Review
92
Preclinical
0
Other
14

Living document — last change September 8, 2026: Cancer page updated. 8 recent updates logged.

Pooled evidence across studies

PubMed
  • OS: HR 0.69 (0.26–1.31 across studies) · (regimen unspecified)
    12 studies · 25% agree · heterogeneous · 1 flagged3885472534169090
  • OS: 38 months (27–51 across studies) · cisplatin + ifosfamide + taxol + carboplatin
    5 studies · 40% agree · heterogeneous17451459
  • PFS: 25.38 months (17.53–27.83 across studies) · PARP inhibitor (PARPi)
    4 studies · 75% agree · moderate · 1 flagged40556673
  • Tumor response: 23.5% (9.4–31 across studies) · (regimen unspecified)
    4 studies · 0% agree · heterogeneous12618869
  • PFS: HR 0.39 (0.36–0.72 across studies) · PARP inhibitor (PARPi)
    3 studies · 67% agree · moderate · 1 flagged40556673
  • OS: 18.7 months (6–28 across studies) · platinum-based chemotherapy + surgery + chemotherapy + radiation
    3 studies · 33% agree · heterogeneous21740740
  • 1-year OS: 58% (29–71 across studies) · platinum-based chemotherapy + surgery + chemotherapy + radiation
    3 studies · 33% agree · heterogeneous21740740
  • 5-year OS: 47.55% (42.5–52.6 across studies) · (regimen unspecified)
    2 studies · 100% agree · consistent38072401
  • OS: 33.5 months (30–37 across studies) · paclitaxel + carboplatin + ifosfamide
    2 studies · 100% agree · consistent35007153
  • PFS: 15.5 months (15–16 across studies) · paclitaxel + carboplatin + ifosfamide
    2 studies · 100% agree · consistent35007153
  • Presentation stage: 38.099999999999994% (16.9–59.3 across studies) · (regimen unspecified)
    2 studies · 0% agree · heterogeneous38854725

Numbers pooled deterministically across 35 published studies that passed our figure-accuracy checks — a quick synthesis, not a formal meta-analysis. Updated 8/31/2026.

Compounds compared by evidence

PubMed

How to read this: Ranked by the strength and volume of the evidence — NOT by how well a treatment works. A higher rank means a compound has been studied more, or in stronger study designs (e.g. randomized trials over lab studies), not that it produces better outcomes. The effect column shows the largest pooled figure reported, not a head-to-head comparison.

#CompoundEvidence strengthStudiesLargest pooled effect
1Ifosfamide OtherHuman trial / meta-analysis4—
2Carboplatin OtherHuman trial / meta-analysis3—
3Paclitaxel OtherHuman trial / meta-analysis3OS: 33.5 mo
4Cisplatin ChemotherapyHuman trial / meta-analysis2OS: 38 mo
5Taxol OtherHuman trial / meta-analysis2—
6Cyclophosphamide ChemotherapyHuman trial / meta-analysis1—
7Dacarbazine OtherHuman trial / meta-analysis1—
8Doxorubicin ChemotherapyHuman trial / meta-analysis1—
9Relacorilant OtherHuman trial / meta-analysis1—
10Trastuzumab Deruxtecan Targeted therapyHuman · observational1—
11Trastuzumab-Deruxtecan (T-Dxd) Targeted therapyHuman · observational1—
12Bevacizumab OtherInsufficient evidence1—
13Niraparib †Rx Targeted therapyInsufficient evidence1—

Ranked across 13 compounds with published studies for this cancer. Updated 8/31/2026.

Medicines & supplements studied for Ovarian Carcinosarcoma

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Ovarian Carcinosarcoma, ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 13

IfosfamideHuman trial / meta-analysisReported positive3 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–51 across 9 studies

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Effect sizes reported in only 2 of 4 studies.
Chemotherapy4 studiesFull profile →
CarboplatinHuman trial / meta-analysisReported positive2 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–51 across 9 studies

Most authoritative study: Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

ChemotherapyFDA approved3 studiesFull profile →
CisplatinHuman trial / meta-analysisMixed results2 human1 animal

Includes human trial or meta-analysis evidence.

Largest credible effect: median survival for the entire cohort 38 mo, n=22 PMID 17451459 · median-survival values 27–51 across 5 studies

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Effect sizes reported in only 2 of 3 studies.
ChemotherapyFDA approved3 studiesFull profile →
PaclitaxelHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–37 across 4 studies

Most authoritative study: Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Effect sizes reported in only 2 of 3 studies.
ChemotherapyFDA off-label3 studiesFull profile →
TaxolHuman trial / meta-analysisInconclusive2 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median survival for the entire cohort 38 mo, n=22 PMID 17451459 · median-survival values 27–51 across 5 studies

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Effect sizes reported in only 1 of 2 studies.
Other2 studiesFull profile →
CyclophosphamideHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

No numeric effect sizes reported · Based on a single study.
ChemotherapyFDA off-label1 studyFull profile →
DacarbazineHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

No numeric effect sizes reported · Based on a single study.
ChemotherapyFDA off-label1 studyFull profile →
DoxorubicinHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

No numeric effect sizes reported · Based on a single study.
ChemotherapyFDA approved1 studyFull profile →
RelacorilantHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: PFS HR 0.66, p P = .038, n=178 PMID 37364223 · hazard ratios 0.36–0.67 across 3 studies

Most authoritative study: Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Based on a single study.
Targeted therapyFDA approvedPhase 21 studyFull profile →
Trastuzumab DeruxtecanHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).
Targeted therapyFDA off-label2 studiesFull profile →
Trastuzumab-Deruxtecan (T-Dxd)Human · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
Targeted therapy1 studyFull profile →
BevacizumabInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: number_of_chemotherapy_cycles 6, n=1 PMID 35949347 · effect sizes 4.55–6 across 3 studies

Most authoritative study: Management of a rare ovarian carcinosarcoma: A case report and literature review

No human studies yet · Based on a single study.
Other1 studyFull profile →
Niraparib †RxInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: number_of_chemotherapy_cycles 6, n=1 PMID 35949347 · effect sizes 4.55–6 across 3 studies

Most authoritative study: Management of a rare ovarian carcinosarcoma: A case report and literature review

No human studies yet · Based on a single study.
Targeted therapy1 studyFull profile →

What recent studies report in Ovarian Carcinosarcoma

These are reviewed studies whose abstracts concern Ovarian Carcinosarcoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Ovarian Carcinosarcoma. Most are early lab, animal, or small human studies, and findings often conflict.

40 studies19 human1 animal⚠ Conflicting evidenceMechanism (9)Trial (4)

Tracking 40 published studies of Ovarian Carcinosarcoma: 19 in humans, 1 in animals, 20 reviews/other.

Reported direction across studies: 16 positive, 9 mixed, 5 negative, 10 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Ovarian Carcinosarcoma.

Compounds with studies mentioning Ovarian Carcinosarcoma

Ifosfamide (4)Cisplatin (3)Carboplatin (3)Paclitaxel (3)Trastuzumab deruxtecan (2)Taxol (2)Trastuzumab deruxtecan t dxd (1)Relacorilant (1)Bevacizumab (1)Niraparib (1)Cyclophosphamide (1)Dacarbazine (1)Doxorubicin (1)
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 57

Clinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas With an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Apr 2026 · retrospective case series

tubo-ovarian carcinosarcomaovarian carcinosarcomafallopian tube neoplasm

This single-institution study reviewed 57 tubo-ovarian carcinosarcomas with median follow-up of 32.3 months. Most tumors (51/57, 89%) were p53-abnormal; a small subset (5/57, 9%) were p53 wild-type and all five had canonical KRAS codon 12 mutations and distinct endometrioid histology. The authors report the first primary POLE-mutated OCS in a patient with Lynch syndrome. KRAS-mutated tumors occurred at younger ages and lower stage but recurred in 2 of 5 patients.

Reported effects: median_follow_up 32.3 mo, n=57 · 5-year survival stage I/II 71%, n=57 · +9 more

Key findings
  • The overall median follow-up period was 32.3 months.
  • Five-year survival rates were 71% (stage I/II), 42% (stage III), and 17% (stage IV).
  • Fifty-one (89%) tumors were of the p53-abnormal molecular subtype.
  • Five (9%) tumors were of no specific molecular subtype, and all 5 of these tumors harbored canonical mutations in KRAS (codon 12).
  • The first reported primary POLE-mutated OCS was identified in a patient with Lynch syndrome (assigned as a double-classifier POLE-mutated/mismatch repair-deficient molecular subtype).
  • Compared with the p53-abnormal tumors, KRAS-mutated tumors occurred in younger women at lower stages, but did recur in 2 out of 5 (40%) patients.
  • KRAS-mutated tumors always showed endometrioid rather than high-grade serous morphology and were usually ER, PR, and WT1 negative.
  • Three KRAS-mutated tumors also had at least focal mesonephric-like histology.
Limitations: Single-institution case series (limited generalizability).; Relatively small overall sample size (n=57) and very small KRAS-mutated subgroup (n=5), limiting statistical power and conclusions about that subset.; Retrospective, observational design without experimental/functional validation.; Follow-up median 32.3 months may limit long-term outcome assessment..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed

Animal studyMixed resultsPreclinical onlyTier 2 · animal

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma

Journal of experimental & clinical cancer research : CR · Jan 2026 · High-throughput drug screening in organoid models performed in presence of cisplatin or eribulin, with validation of top combinations in OCS cell line, organoid and PDX models including in vivo PDX experiments.

Cisplatinovarian carcinosarcomahigh-grade serous ovarian cancer (HGSOC)

The authors performed high-throughput drug screens in ovarian carcinosarcoma (OCS) organoid models and validated top combinations in a unique OCS cell line, organoid and PDX models. Eribulin combined with either an EGFR inhibitor (erlotinib) or a MEK inhibitor (mirdametinib/PD0325901) produced synergistic effects in some in vitro models, and modest survival improvements in vivo, but several PDX models exhibited resistance mechanisms (high ABCB1 expression or KRAS mutation) limiting efficacy.

Reported effects: models_with_synergy 2, n=4 · PDX_models_with_resistance 2, n=3

Studied with: erlotinib, mirdametinib, PD0325901, cisplatin.

Key findings
  • High-throughput screens identified eribulin-based combinations as most effective in OCS organoid models, while cisplatin-based combinations were more effective in HGSOC models.
  • Eribulin plus erlotinib or eribulin plus a MEK inhibitor (mirdametinib/PD0325901) were the most effective combinations in OCS models, with synergy seen in two out of four models for each combination.
  • OCS models appear particularly reliant on EGFR and MAPK signalling in vitro, especially in tumours with TP53 mutation.
  • In vivo (PDX) experiments showed only modest survival improvements for eribulin plus erlotinib, and two of three PDX models had resistance mechanisms (high ABCB1 or KRAS activating mutation).
  • KRAS-mutant OCS cell lines and organoids were sensitive to dual EGFR/MAPK targeting, with greater synergy when eribulin was added as a third agent.
Limitations: Preclinical study using in vitro organoids, cell lines and PDX models; no human clinical data reported.; Only modest in vivo survival benefit reported.; Synergy was observed in a subset of models (e.g., two of four organoid models), indicating heterogeneity and limited generalizability.; A small number of PDX models were tested (three), and two showed resistance mechanisms limiting efficacy.; No doses, schedules, or safety/toxicity data in humans provided..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewInconclusiveLimited evidenceTier 4 · clinical

Genomics of ovarian cancers and the potential of precision medicine

Therapeutic advances in medical oncology · Dec 2025 · review

epithelial ovarian cancerhigh-grade serous ovarian cancerovarian clear cell carcinomaendometrioid ovarian carcinomamucinous ovarian carcinomalow-grade serous ovarian carcinomaovarian carcinosarcoma

This review describes the main genomic subtypes of epithelial ovarian cancer and how those differences may help match patients to targeted therapies. It highlights PARP inhibitors, MAPK pathway inhibitors, cell cycle checkpoint inhibitors, immune checkpoint inhibitors, and antibody-drug conjugate approaches that are being investigated for specific ovarian cancer types. The article also notes that resistance to PARP inhibitors remains a problem and that more evidence is needed for effective combination therapies.

Key findings
  • High-grade serous ovarian cancer is linked mainly to homologous recombination repair gene alterations such as BRCA1 and BRCA2.
  • Ovarian clear cell carcinoma is associated with ARID1A and PIK3CA alterations; endometrioid ovarian carcinoma with PIK3CA and KRAS; mucinous ovarian carcinoma with CDKN2A and KRAS; and low-grade serous ovarian carcinoma with MAPK pathway genes such as BRAF and KRAS.
  • PARP inhibitor therapy has improved survival for women with homologous recombination repair defects in high-grade serous ovarian cancer, but acquired resistance remains an issue.
  • The review emphasizes that genomically targeted combination therapies are urgently needed and that some reported responses are preliminary.
Limitations: Review article only; no new experimental or clinical data presented in the abstract.; No quantitative outcomes or effect sizes are reported in the abstract.; The abstract is broad and does not provide trial-level details, sample sizes, or follow-up durations.; Some therapies discussed are preliminary and require further evidence..

The article is about ovarian cancer genomics and targeted therapies, not a single compound experiment.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMixed resultsLimited evidenceTier 3 · early humann = 26

Real-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China

Frontiers in oncology · Jun 2025 · single-center retrospective study

ovarian carcinosarcoma

This single-center retrospective study reviewed 26 patients with ovarian carcinosarcoma treated between March 2012 and October 2023 and recorded baseline features, treatments, and survival. Median progression-free survival (PFS) for the cohort was 17.53 months. Several clinical/pathologic features (ascites ≥500 ml, age ≥58, tumor diameter <10 cm, Ki-67 ≥70%) showed trends toward longer PFS but the reported comparisons were not statistically significant. Four homologous recombination deficiency (HRD)-positive patients who received a PARP inhibitor had a median PFS of 22.68 months.

Reported effects: median PFS (all patients) 17.53 mo, n=26 · PFS, ascites ≥500 ml vs <500 ml 27.83 mo, p p=0.12 · +8 more

Key findings
  • Twenty-six patients met inclusion criteria; the median PFS of all enrolled patients was 17.53 months.
  • Patients with ascites ≥500 ml had PFS 27.83 months vs. 13.7 months (p=0.12, HR 0.72), showing a trend toward better prognosis.
  • Patients age ≥58 years had PFS 22.93 months vs. 13.53 months (p=0.354, HR 0.62), showing a trend toward better prognosis.
  • Patients with tumor diameter <10 cm had PFS 27.83 months vs. 12.80 months (p=0.095, HR 0.36), showing a trend toward better prognosis.
  • Patients with Ki-67 ≥70% had PFS 22.93 months vs. 13.53 months (p=0.093, HR 0.39), showing a trend toward better prognosis.
  • Five patients underwent genetic testing; 4 were HRD-positive and treated with a PARP inhibitor. The median PFS of those 4 patients was 22.68 months.
Limitations: Small overall sample size (n=26); Single-center, retrospective design with potential for selection and information bias; Very small genetic-testing subgroup (5 tested; 4 HRD-positive) limits conclusions about PARP inhibitor outcomes; Reported subgroup comparisons showed p-values > 0.05 (described as trends) and thus were not statistically significant; No randomized or controlled comparison reported in the abstract; No details on PARP inhibitor dosing, duration, or toxicity provided in the abstract.

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 8

Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous Component

The American journal of surgical pathology · May 2025 · case series with clinicopathologic evaluation and next-generation sequencing

gynecologic carcinosarcomaendometrial carcinosarcomalower uterine segment carcinosarcomaovarian carcinosarcoma

The authors report a clinicopathologic and genomic analysis of eight gynecologic carcinosarcomas with a mesonephric-like carcinomatous component. Sequencing (done separately for carcinomatous and sarcomatous parts in some tumors) showed identical single-nucleotide variants between components, low tumor mutational burden (<10 mutations/Mb), microsatellite stability, and KRAS codon 12 mutations in all sequenced cases. Additional alterations (eg, PTEN, PIK3CA, ARID1A) were identified in several tumors. This is a small descriptive case series and does not include functional experiments or outcome correlations beyond staging.

Reported effects: n_cases 8, n=8 · mean_age 65.6 · +11 more

Key findings
  • Eight cases of gynecologic MLCS (endometrial, lower uterine segment, and ovarian) were identified and evaluated.
  • Genomic DNA extraction and NGS were performed separately on carcinomatous and sarcomatous components of 4 tumors and on combined components of 2 tumors.
  • The carcinomatous and sarcomatous components were observed to harbor the same single nucleotide variations when sequenced separately.
  • All cases had less than 10 mutations/Mb and were microsatellite stable.
  • All sequenced cases (6/6, 100%) harbored KRAS point mutations in codon 12 (p.G12D n=2; p.G12A n=2; p.G12V n=2).
  • Five cases showed additional alterations including ARID1A, PTEN, PIK3CA, SPOP, TET1, BUB1, LYN and PTPRD.
  • Authors suggest the combination of KRAS and PTEN/PIK3CA alterations is consistent with combined endometrioid and mesonephric differentiation in MLCS.
Limitations: Small sample size (8 cases) limits generalizability.; Only 6 tumors underwent NGS (4 separately by component, 2 combined), so not all cases had component-specific sequencing.; Descriptive molecular profiling without functional validation of mutations.; No survival or treatment-outcome correlations reported beyond FIGO stage..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalReported positiveLimited evidenceTier 3 · early humann = 10

Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

BMC cancer · Dec 2024 · retrospective cohort

Trastuzumab-deruxtecan-t-dxdTrastuzumab-deruxtecanendometrial neoplasmsovarian neoplasmscervical neoplasmsuterine carcinosarcomauterine leiomyosarcomauterine serous carcinomaovarian carcinosarcomahigh-grade serous ovarian carcinomamucinous ovarian carcinomasquamous cervical carcinoma

This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.

Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 · partial responses 5, n=10 · +2 more

Key findings
  • 10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
  • Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
  • Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
  • HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
  • Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
  • Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
  • Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
  • Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
  • Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportReported positiveLimited evidenceTier 3 · early humann = 1

A case of ovarian carcinosarcoma with germline BRCA2 pathogenic variant

The journal of obstetrics and gynaecology research · Dec 2024 · case report

ovarian carcinosarcomahigh-grade serous carcinomaductal carcinoma in situ (breast)

This is a single-case report of a 43-year-old woman with advanced (stage IIIB) ovarian carcinosarcoma who was found to have a germline BRCA2 pathogenic variant. After surgery and postoperative adjuvant chemotherapy she received maintenance therapy with a PARP inhibitor for 25 months and had no recurrence during that period. The authors note a concurrent ductal carcinoma in situ in the left breast and suggest PARP inhibitors may be effective as maintenance therapy in this setting, but this is a single case.

Reported effect: maintenance duration without recurrence 25 mo, n=1

Studied with: postoperative adjuvant chemotherapy.

Key findings
  • Patient: 43-year-old woman with an 8-cm right ovarian mass and family history of prostate and uterine/ovarian cancer.
  • Histology: carcinosarcoma consisting of high-grade serous carcinoma and sarcomatous components including cartilage.
  • Staging: advanced stage IIIB (FIGO 2014).
  • Genetics: germline BRCA2 pathogenic variant identified.
  • Treatment course: right salpingo-oophorectomy, radical surgery three weeks later, postoperative adjuvant chemotherapy, then maintenance therapy with a PARP inhibitor.
  • Outcome: maintenance PARP inhibitor continued for 25 months without recurrence.
  • Additional finding: ductal carcinoma in situ in the left breast at first visit.
Limitations: Single-patient case report (n=1), so findings are not generalizable.; No control or comparison group.; Specific PARP agent and dosing not reported.; Observational uncontrolled follow-up; cannot establish causality between PARP maintenance and lack of recurrence..

Single-case report describing PARP inhibitor maintenance in a BRCA2-mutant ovarian carcinosarcoma with 25 months recurrence-free during follow-up.

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 32

Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations

Virchows Archiv : an international journal of pathology · Dec 2024 · targeted next-generation sequencing of tumor specimens (molecular profiling)

tubo-ovarian carcinosarcoma

The authors performed targeted next-generation sequencing of 32 tubo-ovarian carcinosarcoma specimens (including 7 serous effusions) covering 50 genes. They found 31 mutations in 25 of 32 tumors, with TP53 alterations predominant (25 mutations in 24 tumors); other mutations (RB1, MET, KRAS, PTEN, KIT) were rare. Patient-matched specimens shared the same TP53 mutation, and specimens with no detected mutations were more frequent among serous effusions than surgical specimens. The authors conclude TP53 mutations dominate the molecular landscape and note it is uncertain whether effusion-derived cells differ from solid lesions.

Reported effects: specimens_n 32, n=32 · patients_n 25, n=25 · +11 more

Key findings
  • Specimens (n=32) consisted of 25 biopsies/surgical resection specimens and 7 serous effusions (6 peritoneal, 1 pleural) from 25 patients.
  • Targeted next-generation sequencing covered 50 unique genes.
  • A total of 31 mutations were found in 25 of the 32 tumors studied, of which 1 had 3 mutations, 4 had 2 different mutations, and 20 had a single mutation.
  • The most common mutations were in TP53 (n=25 in 24 tumors; 1 tumor with 2 different mutations).
  • Less common mutations were found in RB1 (n=2), MET (n=1), KRAS (n=1), PTEN (n=1), and KIT (n=1).
  • Patient-matched specimens harbored the same TP53 mutation.
  • Tumors with no detected mutations were more common in serous effusion specimens (3/7; 43%) compared with surgical specimens (4/25; 16%).
Limitations: Small sample size (32 specimens from 25 patients).; Use of a targeted 50-gene panel limits detection to predefined genes and may miss other relevant alterations.; Observational molecular profiling without functional validation of variants.; Unclear generalizability given limited anatomic sampling and small number of effusion specimens..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveModerate evidenceTier 3 · early humann = 122

STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours

Histopathology · Nov 2024 · immunohistochemical analysis of a cohort of human tumours (122 cases) including STK11 adnexal tumours and morphological mimics

STK11 adnexal tumourovarian neoplasmsovarian endometrioid carcinomatubo-ovarian high-grade serous carcinomaovarian mesonephric-like adenocarcinomaovarian carcinosarcomaperitoneal malignant mesotheliomapelvic plexiform leiomyomaovarian solid pseudopapillary tumourgranulosa cell tumourSertoli-Leydig cell tumourLeydig cell tumourSertoli cell tumoursteroid cell tumourfemale adnexal tumour of Wolffian originextra-ovarian sex cord-stromal tumour

Researchers performed STK11 (LKB1) immunohistochemistry on 122 human tumour samples, including 17 STK11 adnexal tumours and 105 morphological mimics. All 17 STK11 adnexal tumours showed complete loss of cytoplasmic STK11 staining. Nearly all other tumour types retained cytoplasmic STK11 staining, with the exception of one endometrioid carcinoma with mucinous differentiation showing complete loss and one high-grade serous carcinoma showing subclonal loss. The authors conclude STK11 IHC is a highly sensitive and specific marker for distinguishing STK11 adnexal tumour in the appropriate morphological context and could obviate confirmatory molecular testing.

Reported effects: total tumours tested 122, n=122 · STK11 adnexal tumours included 17, n=17 · +3 more

Key findings
  • IHC for STK11 was performed on 122 tumours, including 17 STK11 adnexal tumours and 105 morphological mimics (full list of mimics given in abstract).
  • All STK11 adnexal tumours showed complete loss of cytoplasmic staining for STK11.
  • All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high-grade serous carcinoma with subclonal loss.
  • Authors conclude STK11 IHC is a highly sensitive and specific immunohistochemical marker for distinguishing STK11 adnexal tumour from histological mimics and may obviate the need for confirmatory molecular studies in the appropriate morphological context.
Limitations: Small number of STK11 adnexal tumours (n=17), reflecting rarity of the entity.; Study reports a single cohort with no external validation cohort mentioned in the abstract.; Potential selection bias because tumour types were a selected set of morphological mimics.; Abstract does not report blinding, interobserver reproducibility, or diagnostic performance statistics (sensitivity/specificity values) beyond descriptive counts.; Two non-STK11 tumours showed loss/subclonal loss of STK11, indicating imperfect specificity in this cohort..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 1

Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma

Journal of Zhejiang University. Science. B · Aug 2024 · single-cell RNA sequencing (scRNA-seq) analysis of resected primary tumor with comparison to published scRNA-seq datasets

ovarian carcinosarcomahigh-grade serous ovarian carcinoma

The authors performed single-cell RNA sequencing on a resected primary ovarian carcinosarcoma and compared the data with published high-grade serous ovarian carcinoma and other OCS datasets. They identified malignant epithelial and malignant mesenchymal cells, four epithelial subclusters (one with high BRCA1 and TOP2A expression linked to cell cycle and drug-resistance features), and a mesenchymal subcluster C14 with an OCS-specific expression pattern. They also report FGF and PTN signaling as major pathways mediating epithelial–mesenchymal communication. The study provides a single-cell transcriptomic resource for exploring OCS heterogeneity.

Key findings
  • Both malignant epithelial and malignant mesenchymal cells were observed in the OCS patient sample.
  • Four epithelial cell subclusters were identified; epithelial subcluster 4 had high BRCA1 and TOP2A expression and was related to drug resistance and cell cycle.
  • Intercellular interaction analysis indicated FGF and PTN signaling as main pathways contributing to communication between epithelial and mesenchymal cells.
  • A mesenchymal subcluster (C14) showed OCS-specific expression (elevated CYP24A1, COL23A1, CCK, BMP7, PTN, WIF1, and IGF2) and distinct characteristics compared with another published OCS tumor and normal ovarian tissue.
Limitations: Analysis appears to be from a single resected tumor/patient, limiting generalizability.; Observational transcriptomic profiling without functional validation of identified pathways or subclusters.; No clinical outcome, treatment response, or longitudinal data reported.; Comparisons rely on previously published datasets rather than additional contemporaneous samples..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportReported negativeLimited evidenceTier 3 · early humann = 1

Sigmoido-ovarian fistula complicating ovarian carcinosarcoma: a case report

Annals of medicine and surgery (2012) · Jul 2024 · case report

ovarian carcinosarcoma

This is a case report of a 67-year-old woman who presented with abdominal pain and was found at surgery to have an ovarian carcinosarcoma fistulized into the sigmoid colon with pelvic peritonitis. She underwent en-bloc resection with formation of a terminal stoma; postoperative imaging showed diffuse lymph node metastases and she was scheduled for chemotherapy. The authors state that fistulization into the large intestine is a rare complication that worsens prognosis and that surgery plus adjuvant therapy are generally required.

Key findings
  • Spontaneous fistulization of ovarian carcinosarcoma into the digestive tract is rare.
  • The patient presented with abdominal pain; CT suggested a perforated sigmoid tumor with peri-colonic abscess and pneumoperitoneum.
  • Intraoperative findings were an ovarian tumor fistulized to the sigmoid colon with peritonitis.
  • An en-bloc resection with terminal stoma was performed.
  • Postoperative radiology revealed diffuse lymph node metastasis; the patient was scheduled for chemotherapy.
  • Authors note fistulization can cause tumor superinfection and pelvic peritonitis and may prevent the use of neoadjuvant chemotherapy, worsening chances of complete cytoreduction.
  • Conclusion: fistulization to the large intestine worsens prognosis; surgery is mandatory and adjuvant therapy is mostly needed.
Limitations: Single-patient case report limits generalizability.; No control or comparison group.; No quantitative or long-term outcome data reported (e.g., survival, response to chemotherapy).; Limited detail on pathology, operative findings, and postoperative course in the abstract..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalReported negativeModerate evidenceTier 3 · early humann = 47028

Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes

Frontiers in oncology · May 2024 · multi-cohort cross-sectional study

ovarian carcinosarcoma (OCS)high-grade serous ovarian carcinoma (HGSOC)endometrioid ovarian carcinoma (EnOC)clear cell ovarian carcinoma (CCOC)mucinous ovarian carcinoma (MOC)low-grade serous ovarian carcinoma (LGSOC)

The authors performed a multi-cohort cross-sectional analysis using Scottish and SEER registries to compare characteristics and overall survival between ovarian carcinosarcoma (OCS) and other major ovarian cancer histotypes. They found OCS patients were older at diagnosis, presented frequently with advanced stage, and had significantly shorter survival than most other histotypes, including when adjusted for prognostic factors; this poor outcome was evident even for early-stage disease.

Reported effects: Scottish cohort sample size 2082, n=2082 · SEER cohort sample size 44946, n=44946 · +14 more

Key findings
  • Study cohorts: Scotland (n=2082) and SEER (n=44946).
  • OCS patients had median ages at diagnosis of 69 (Scottish) and 67 (SEER) and demonstrated the shortest survival on univariable analysis.
  • Within the Scottish cohort, 59.3% and 16.9% of OCS patients presented with FIGO stage III and IV disease, respectively.
  • Multivariable analysis showed other histotypes had lower hazards (better survival) than OCS in both cohorts: Scottish multivariable HRs vs OCS — HGSOC 0.45, EnOC 0.39, LGSOC 0.26, MOC 0.43.
  • SEER multivariable HRs vs OCS — HGSOC 0.59, EnOC 0.34, LGSOC 0.30, MOC 0.81.
  • Within SEER, CCOC had a multivariable HR 0.63 (95% CI 0.58-0.68) versus OCS, while in the Scottish cohort the multivariable HR for CCOC was 1.05 (95% CI 0.74-1.51).
  • OCS was associated with the poorest survival among histotypes even for early-stage disease across both cohorts; in late-stage disease OCS, MOC and CCOC had the poorest survival.
Limitations: Observational cross-sectional design (not randomized), so causal inference is limited.; Potential for residual confounding despite multivariable adjustment.; Some results differed between cohorts (e.g., CCOC comparison), indicating cohort heterogeneity or population differences.; No intervention or treatment effects were tested..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Ovarian Carcinosarcoma →

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Ifosfamide31—2
Carboplatin21—1
Cisplatin22—1
Paclitaxel1——1
Taxol21—1
Cyclophosphamide1——1
Dacarbazine1——1
Doxorubicin1——1
Relacorilant11—1
Trastuzumab Deruxtecan1———
Trastuzumab-Deruxtecan (T-Dxd)1———
Bevacizumab————
Niraparib †Rx————

Study mix

40 published studies by what they were done in. Lab and animal findings often do not carry over to people.

19 Human1 Animal20 Review/other
Reported directionReported positive16Mixed results9Reported negative5Inconclusive10

Compounds with reported-positive results in Ovarian Carcinosarcoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Paclitaxel3 positive1 human
Limitations: Single-patient case report — results not generalizable.; Short follow-up duration (6 months) — no long-term outcomes reported.; No control or comparator group to attribute benefit to any specific component of the management.; Bevacizumab was discontinued (and had toxicity/cost issues), complicating interpretation of the combined regimen's effect.; No dose details provided for niraparib or chemotherapeutic agents.; Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision..
Cited positive studies (3)
Trastuzumab Deruxtecan2 positive1 human
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (2)
Carboplatin2 positive2 human
Limitations: Single-patient case report — results not generalizable.; Short follow-up duration (6 months) — no long-term outcomes reported.; No control or comparator group to attribute benefit to any specific component of the management.; Bevacizumab was discontinued (and had toxicity/cost issues), complicating interpretation of the combined regimen's effect.; No dose details provided for niraparib or chemotherapeutic agents.; Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision..
Cited positive studies (2)
Ifosfamide2 positive3 human
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract.; Ovarian carcinosarcoma is a low-frequency disease, which has made prospective trials difficult to perform (as stated in the abstract).; Many patients present with poor performance status, limiting the applicability of combination chemotherapy for some individuals.; Aggressive cytoreductive surgery is associated with higher complication rates (limiting generalizability and increasing procedural risk)..
Cited positive studies (2)
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Cited positive studies (1)
Preclinical only: lab / animal (2)
Bevacizumab1 positive
Limitations: Single-patient case report — results not generalizable.; Short follow-up duration (6 months) — no long-term outcomes reported.; No control or comparator group to attribute benefit to any specific component of the management.; Bevacizumab was discontinued (and had toxicity/cost issues), complicating interpretation of the combined regimen's effect.; No dose details provided for niraparib or chemotherapeutic agents..
Cited positive studies (1)
Niraparib †Rx1 positive
Limitations: Single-patient case report — results not generalizable.; Short follow-up duration (6 months) — no long-term outcomes reported.; No control or comparator group to attribute benefit to any specific component of the management.; Bevacizumab was discontinued (and had toxicity/cost issues), complicating interpretation of the combined regimen's effect.; No dose details provided for niraparib or chemotherapeutic agents..
Cited positive studies (1)

Evidence at a glance: compounds studied in Ovarian Carcinosarcoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

IfosfamideHuman trial / meta-analysisReported positive3 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–51 across 9 studies

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Effect sizes reported in only 2 of 4 studies.
CarboplatinHuman trial / meta-analysisReported positive2 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–51 across 9 studies

Most authoritative study: Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

CisplatinHuman trial / meta-analysisMixed results2 human1 animal

Includes human trial or meta-analysis evidence.

Largest credible effect: median survival for the entire cohort 38 mo, n=22 PMID 17451459 · median-survival values 27–51 across 5 studies

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Effect sizes reported in only 2 of 3 studies.
PaclitaxelHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–37 across 4 studies

Most authoritative study: Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Effect sizes reported in only 2 of 3 studies.
TaxolHuman trial / meta-analysisInconclusive2 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median survival for the entire cohort 38 mo, n=22 PMID 17451459 · median-survival values 27–51 across 5 studies

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

Effect sizes reported in only 1 of 2 studies.
CyclophosphamideHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

No numeric effect sizes reported · Based on a single study.
DacarbazineHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

No numeric effect sizes reported · Based on a single study.
DoxorubicinHuman trial / meta-analysisInconclusive1 human

Includes human trial or meta-analysis evidence.

Most authoritative study: Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma

No numeric effect sizes reported · Based on a single study.
RelacorilantHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: PFS HR 0.66, p P = .038, n=178 PMID 37364223 · hazard ratios 0.36–0.67 across 3 studies

Most authoritative study: Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Based on a single study.
Trastuzumab DeruxtecanHuman · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Effect sizes reported in only 1 of 2 studies · All studies are small (n < 30).
Trastuzumab-Deruxtecan (T-Dxd)Human · observationalReported positive1 human

Human observational evidence only — no trials.

Largest credible effect: median PFS 5.4 mo [0.8–9.8], n=10 PMID 39639215 · effect sizes 1–5 across 3 studies

Most authoritative study: Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies

Based on a single study.
BevacizumabInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: number_of_chemotherapy_cycles 6, n=1 PMID 35949347 · effect sizes 4.55–6 across 3 studies

Most authoritative study: Management of a rare ovarian carcinosarcoma: A case report and literature review

No human studies yet · Based on a single study.
Niraparib †RxInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: number_of_chemotherapy_cycles 6, n=1 PMID 35949347 · effect sizes 4.55–6 across 3 studies

Most authoritative study: Management of a rare ovarian carcinosarcoma: A case report and literature review

No human studies yet · Based on a single study.

What the research shows for Ovarian Carcinosarcoma

A plain-language summary of the reviewed studies OncoForge tracks for Ovarian Carcinosarcoma. It reports what those studies described, not a claim that any compound or therapy helps or harms Ovarian Carcinosarcoma. Most of this evidence is early, and findings often conflict.

  • Studies report that ovarian carcinosarcoma is a rare, aggressive tumor and most published evidence consists of retrospective reviews, small observational series, case reports, and a few trials that include carcinosarcoma among other histologies.
  • Studies reported that platinum-based chemotherapy (carboplatin or cisplatin) is commonly used after cytoreductive surgery and that retrospective series suggested possible activity, but the data are limited, largely nonrandomized, and not definitive.
  • Studies report a randomized phase III trial that enrolled patients with uterine or ovarian carcinosarcoma comparing paclitaxel+carboplatin versus paclitaxel+ifosfamide; in the uterine subgroup the carboplatin regimen was noninferior and had longer median overall survival, but ovarian‑specific outcomes were not clearly reported separately.
  • Studies report that newer agents and combinations have been explored in small or early‑phase studies: for example, relacorilant added to nab‑paclitaxel showed mixed results in a heterogeneous recurrent platinum‑resistant ovarian cancer population, and trastuzumab deruxtecan produced modest PFS in a small retrospective series of HER2‑expressing gynecologic tumors including ovarian cases.
  • Studies report genomic and sequencing analyses showing recurrent TP53 alterations, some homologous recombination deficiency and germline pathogenic variants in a minority of cases, indicating molecular heterogeneity but with uncertain therapeutic implications.

Compounds studied in Ovarian Carcinosarcoma

Carboplatin2 studies
Studies reported that carboplatin is commonly used after cytoreductive surgery for ovarian carcinosarcoma and that retrospective series have suggested possible activity; however, the evidence is limited, largely nonrandomized, and not definitive.
Paclitaxel1 study
In these studies, paclitaxel was studied (including in combination with carboplatin or ifosfamide) and featured in a randomized trial that included ovarian carcinosarcoma patients, but subgroup-specific conclusions for ovarian cases were limited.
Ifosfamide2 studies
In these studies, ifosfamide was used as a comparator chemotherapy (often combined with paclitaxel) in trials that enrolled uterine and ovarian carcinosarcoma, with limited and mixed comparative data reported.
Relacorilant1 study
In these studies, relacorilant was tested in a phase II trial added to nab‑paclitaxel in recurrent platinum‑resistant ovarian and related epithelial cancers (not specifically ovarian carcinosarcoma); an intermittent relacorilant schedule showed some improvement in progression-free survival in a heterogeneous ovarian cohort, but evidence is preliminary.
Trastuzumab Deruxtecan1 study
In these studies, trastuzumab deruxtecan was reported in a small retrospective cohort of HER2‑expressing gynecologic cancers that included ovarian cases and had a median progression‑free survival of about 5.4 months, but the sample was small and nonrandomized.
Cisplatin1 study
In these studies, cisplatin was included in small retrospective treatment series of ovarian carcinosarcoma, and those observational data were inconclusive regarding benefit.

Supportive & alternative options discussed

  • Exercise / prehabilitation: Also discussed as a supportive option for people with ovarian carcinosarcoma to help maintain fitness and reduce treatment-related fatigue, though this is not a finding from the studies summarized above.
  • Mind–body (MBSR / CBT): Also discussed as a supportive option for managing stress, anxiety, and quality of life during cancer care for people with ovarian carcinosarcoma; this is a general supportive approach, not a result of the studies above.
  • Acupuncture: Also discussed as a supportive option for symptom control (for example, pain or nausea) in ovarian cancer care in general; this was not evaluated in the studies summarized here for ovarian carcinosarcoma.
  • Mistletoe (VAE): Also discussed in some integrative contexts as a supportive option alongside conventional care for gynecologic cancers, but this was not addressed by the studies summarized above.

What we don’t know yet

  • Do specific chemotherapy regimens (for example, paclitaxel+carboplatin versus alternatives) provide superior outcomes specifically for ovarian carcinosarcoma patients, as opposed to mixed uterine/ovarian cohorts?
  • Can targeted therapies such as HER2‑directed agents (e.g., trastuzumab deruxtecan) provide meaningful clinical benefit for HER2‑positive ovarian carcinosarcoma, and in which patients?
  • Is relacorilant or other novel agents active against ovarian carcinosarcoma specifically, since available trials enrolled heterogeneous ovarian cancer populations rather than carcinosarcoma alone?
  • Which molecular biomarkers (TP53, HRD, germline variants, others) predict response to chemotherapy, targeted agents, or immunotherapy in ovarian carcinosarcoma?
  • What are the optimal dosing, safety, and long‑term outcomes of systemic therapies in ovarian carcinosarcoma, given the scarcity of prospective data focused solely on this subtype?
Overall, the evidence for systemic and targeted treatments in ovarian carcinosarcoma is limited and mainly comes from retrospective series, pooled studies, and small or heterogeneous trials, so findings should be viewed as preliminary and inconclusive for this specific tumor type.

Clinical trials in Ovarian Carcinosarcoma

21 ongoing · 29 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
15 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Ovarian Carcinosarcoma — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN Foundation ↗ — Copay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell Foundation ↗ — Copay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistance ↗ — Limited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family Reach ↗ — Help with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMeds ↗ — Searchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Interactions & safety to check: Ovarian Carcinosarcoma

This is not a complete interaction check. It only covers the compounds we track and the signals reported in studies. A drug or supplement not listed here is not therefore safe. Bring your full medication and supplement list to your pharmacist and oncologist before changing anything.

Potential interactions: highest-stakes first

  • Niraparib †Rx×CYP1A2 inhibitorshigh-stakeslow
    Monitor: Modest exposure increase (e.g., fluvoxamine).
  • Niraparib †Rx×P-gp substrateshigh-stakeslow
    Monitor: Potential competition (e.g., digoxin).
  • Niraparib †Rx×Bevacizumablow
    Synergize: Complementary PFS extension in ovarian.

Safety considerations

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →

Biomarkers — what to test for, and what it could unlock

PubMedFDA

A positive result may make you eligible for the linked options — it doesn’t mean a treatment will work, and not every test is standard everywhere. Confirm testing and results with your care team.

Many of these can be checked at once from a single tumor (or blood) sample — ask your team whether a comprehensive multi-gene (NGS) panel is right for you, rather than one test at a time.

BRCA1/2 / HRDDNA repair · occasionalPrognostic / other

How it’s tested: HRD/BRCA

Pre-screen recruiting trials for BRCA1/2 / HRD →

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

Desmin / myogenin / MyoD1myogenic differentiation · variablePrognostic / other

Pre-screen recruiting trials for Desmin / myogenin / MyoD1 →

EGFRgrowth factor receptor · occasionalPrognostic / other

Pre-screen recruiting trials for EGFR →

ER/PRhormone receptors · variablePrognostic / other

How it’s tested: HER2 (IHC/ISH)

Pre-screen recruiting trials for ER/PR →

HER2growth factor receptor · rarePrognostic / other

How it’s tested: HER2 (IHC/ISH)

Pre-screen recruiting trials for HER2 →

Ki-67proliferation index · commonPrognostic / other

Pre-screen recruiting trials for Ki-67 →

MMR/MSIDNA repair · rarePrognostic / other

How it’s tested: MMR/MSI

Pre-screen recruiting trials for MMR/MSI →

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

p16cell cycle · commonPrognostic / other

Pre-screen recruiting trials for p16 →

p53tumor suppressor · abnormalPrognostic / other

Pre-screen recruiting trials for p53 →

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

PD-L1immune checkpoint · variablePrognostic / other

How it’s tested: MMR/MSI

Pre-screen recruiting trials for PD-L1 →

VEGF / HIF-1αangiogenesis / hypoxia · unknownPrognostic / other

Pre-screen recruiting trials for VEGF / HIF-1α →

Marker → medicine links are derived from this page’s published claims for Ovarian Carcinosarcoma; resistance and companion-diagnostic notes appear only where an established, sourced entry exists.

Go deeper

Questions to ask your oncologist

  • Is my tumor epithelial-dominant, sarcoma-dominant, or truly mixed — and how does that affect treatment options?
  • How aggressive is my specific case based on stage, grade, and pathology markers?
  • What is my likely prognosis, and how do factors like BRCA/HRD or complete cytoreduction influence survival?
  • Can cytoreductive surgery be complete (R0) or optimal in my case, and what risks are involved?
  • Should I seek surgery at a high-volume center experienced in ovarian carcinosarcoma?
  • If surgery is not possible, what other disease-control strategies are available?
  • If chemo is planned, which regimen is best for me — platinum/taxane (epithelial-leaning) or anthracycline/ifosfamide (sarcoma-leaning)?
  • How many cycles of chemotherapy are recommended, and what is the expected benefit?
  • What are the most common side effects of these regimens, and how are they managed?
  • If I become resistant to platinum, what other systemic therapies could be considered?
  • Have my tumor and blood been tested for BRCA, HRD, MSI/MMR, PD-L1, and HER2?
  • If I have BRCA or HRD, would a PARP inhibitor be an option?
  • If PD-L1 positive, could I qualify for immunotherapy or a clinical trial?
  • Are there other molecular alterations (like p53, PI3K/AKT/mTOR, CLDN18.2) that could influence future treatment?
  • Which clinical trials are available for ovarian carcinosarcoma or mixed Müllerian tumors?
  • Are there basket trials (based on biomarkers, not tumor type) that I might qualify for?
  • Do I need to travel to a major cancer center for these trials, or are there remote/affiliate sites?
  • How will we monitor whether treatment is working — imaging, CA-125, or symptoms?
  • How often will I need CT, MRI, or PET scans?
  • At what point would we decide to change or stop a therapy if it’s not working?
  • What supportive care options (pain, nutrition, exercise) can improve my tolerance to treatment?
  • Are there safe integrative or adjunctive therapies that might help without interfering with chemo?
  • What red flags should I watch for at home that mean I need urgent medical attention?
  • Are fertility or menopause issues relevant in my situation, and can they be managed alongside treatment?
  • What is the role of palliative care — should I start it now or later?
  • How do we balance aggressive treatment with quality of life?
  • What advance care planning steps should I consider while still pursuing treatment?

Find a trial

Search active and completed trials at these registries:

Citations

  1. Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review (2025)

    PMC (Gynecologic Oncology Reports)

    • Epidemiology/rarity and prognosis
    • Rhabdomyosarcoma differentiation
    • Pathology markers (biphasic, p53, Ki-67)
    • Spread, staging, management
    • Targeted/immuno hooks (HRD/MSI)

  2. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma (2022)

    Nature (British Journal of Cancer)

    • Overview: rare biphasic tumor; poor prognosis
    • Pathology markers; spread; advanced stage
    • Surgery/chemo; prognostic drivers

  3. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management by PARP Inhibition and Immunotherapy (2024)

    PMC (Gynecologic Oncology)

    • Biomarkers: BRCA/HRD, MSI/MMR, PD-L1, HER2
    • Pathways: DNA repair, PI3K/AKT/mTOR, VEGF, PD-1/PD-L1
    • Targeted/immuno: PARP, IO; monitoring

  4. Predictive biomarkers for targeted therapy in daily anatomic pathology practice of ovarian cancer (2025)

    BMC Surgical & Experimental Pathology

    • Biomarkers: p53, ER/PR, BRCA/HRD, MSI, PD-L1, HER2, EGFR, Ki-67, p16
    • Markers: WT1, PAX8, cytokeratins, desmin, myogenin, vimentin

  5. Frontiers of Ovarian Carcinosarcoma (2023)

    Springer (Current Treatment Options in Oncology)

    • Epidemiology and prognosis
    • Pathways: EMT, hypoxia/HIF-1α, PI3K/AKT/mTOR, MMPs
    • Management: cytoreductive surgery, platinum/taxane; sarcoma regimens
    • VEGF/anti-angiogenic

  6. Ovarian Cancer Risk Factors (ACS, ongoing)

    American Cancer Society

    • Lifetime risk and risk factors
    • Presentations: bloating, satiety, urinary symptoms, ascites

  7. Ovarian Cancer: Symptoms, Diagnosis & Treatment (Cleveland Clinic, 2023)

    Cleveland Clinic

    • Symptoms and spread (pelvis, nodes, abdomen, intestines, liver, chest)

  8. Ovarian Cancer Staging (OCRA, ongoing)

    Ovarian Cancer Research Alliance

    • FIGO staging; prognosis by stage; surgery for staging/treatment

  9. Ovarian carcinosarcoma: Current developments and future perspectives (2019)

    Critical Reviews in Oncology/Hematology

    • Adjuncts (IVC, hyperthermia, curcumin, EGCG)
    • Contraindications & chemo timing/adjuncts

FAQs

Are there standard protocols for ovarian carcinosarcoma?
  • Care is individualized. Many plans adapt epithelial ovarian and sarcoma regimens based on pathology, biology, stage, and goals. High-volume centers and expert pathology review are valuable.
Is surgery (cytoreduction) always necessary or beneficial?
  • When feasible and safe, optimal cytoreduction can improve outcomes. Benefit depends on stage, distribution, and performance status. Ask whether your case is best served by upfront surgery or neoadjuvant therapy.
Which biomarkers actually matter for OCS?
  • Priority signals include HRD/BRCA, MSI/MMR, PD-L1 (contextual), and rare HER2 overexpression. p53 is almost always abnormal and explains aggressive biology but isn’t directly targetable yet.
How quickly does OCS adapt or become resistant?
  • OCS can pivot within weeks to months. Mechanisms include HR reversion (after PARP), pathway bypass (PI3K/AKT/MAPK), metabolic switching, immune escape (PD-L1 upregulation), and drug efflux.
Do adjuncts work on their own?
  • Adjuncts rarely control OCS alone. They’re best as synergy enhancers—timed around chemo, surgery, or trial agents. Without a cytotoxic or DNA-damaging backbone, adaptation often occurs within weeks.
How should I time adjuncts with chemotherapy?
  • Avoid antioxidant-heavy adjuncts on days when ROS-dependent chemo is given. Hold anti-angiogenic adjuncts in the peri-operative window (often ~2–4 weeks) unless cleared by your team.
Can cycling and multi-pathway strategies reduce resistance?
  • Yes. Alternating or combining pressure across pathways (DNA-damage, metabolic, immune, angiogenic) can limit escape. This must be planned to avoid overlapping toxicity and drug–drug interactions.
How do I tell if an adjunct is helping or hurting?
  • Change one variable at a time, define a short trial window (e.g., 2–4 weeks), track symptoms, labs, and any markers that were informative at baseline, and pre-define stop rules for side effects or no benefit.
Should I use CA-125 to track OCS?
  • Only if it was elevated at baseline and clearly tracks your disease. Otherwise, rely on symptoms, exam, and planned imaging intervals.
What is the role of PARP inhibitors?
  • Discuss if HRD/BRCA-positive and clinically appropriate (maintenance vs treatment settings). Monitor for fatigue, cytopenias, and GI effects; resistance can emerge via HR reversion.
Could immunotherapy help?
  • Benefit is more likely with MSI-H/dMMR or very high TMB; PD-L1 may aid trial eligibility. Responses are variable in OCS; immune-related adverse events require prompt reporting.
What about diet, fasting, or metabolic approaches?
  • Maintain weight and protein intake. If considering fasting/FMD, do so under supervision—avoid if underweight or frail. Metabolic strategies alone seldom control OCS; consider them as tolerance/synergy tools.
Which supplements are risky with my treatment?
  • Supplements that affect CYP3A4/P-gp, anticoagulation, QT interval, or platelet function can interact with chemo/targeted agents. Share a full list with your team and time them safely around infusions.
How often will I be monitored?
  • On active therapy, imaging is commonly every 8–12 weeks (individualize). Track symptoms closely and report changes early; spacing can lengthen on stable maintenance plans.
Should I get a second opinion or pathology review?
  • Yes, when feasible. Mixed histology can be challenging; expert pathology and a gynecologic oncology team can refine diagnosis and options.
How are ascites and pain managed?
  • Use multimodal symptom control. Paracentesis can relieve ascites; diuretics have limited benefit. Early palliative care consults improve quality of life and do not preclude active treatment.
How do clinical trials fit in?
  • Trials are key due to rarity and rapid adaptation. Ask about basket trials accepting HRD/BRCA, MSI-H/dMMR, PD-L1+, or HER2+ signal, and timing relative to lines of therapy.
What should I bring to visits?
  • A prioritized question list, current meds/supplements with doses, treatment side-effect log, goals of care, and a support person. Confirm what to do after-hours and which issues require the ER.
When do I call my team vs go to the ER?
  • Call urgently for red-flag symptoms; go to the ER for fever ≥100.4°F during chemo, chest pain or sudden shortness of breath, severe abdominal pain with no gas/stool, heavy bleeding, confusion, or seizure.

What we don't know yet

  • Few randomized trials specific to ovarian carcinosarcoma: most evidence is extrapolated from epithelial ovarian cancer or uterine carcinosarcoma cohorts.
  • Heterogeneous pathology and mixed histology complicate evidence synthesis: outcomes differ by epithelial vs sarcomatous predominance, but data are often pooled.
  • Limited biomarker-driven studies: BRCA/HRD, MSI, PD-L1, and HER2 testing are inconsistently reported, making it hard to know which subsets truly benefit from targeted or immunotherapies.
  • Small, retrospective case series dominate the literature: most reports have fewer than 50 patients, limiting statistical power and generalizability.
  • Lack of standardized adjunctive therapy evaluation: supportive and integrative strategies (IVC, hyperthermia, diet, supplements) are rarely studied in OCS specifically, leaving patients reliant on indirect evidence.
  • Minimal real-world registry data: population-based databases often underreport or misclassify OCS, making incidence, survival, and treatment-pattern estimates unreliable.
  • Sparse data on recurrence biology: little is known about how carcinoma vs sarcoma compartments evolve after therapy, or how best to target them at relapse.
  • Underrepresentation in clinical trials: most ovarian cancer trials exclude or fail to stratify carcinosarcoma, limiting insights into drug efficacy for this group.
  • No validated treatment algorithms unique to OCS: current guidelines default to high-grade serous ovarian carcinoma protocols, despite clear biological differences.
  • Outcome reporting inconsistency: survival, progression-free survival, and response metrics are often not stratified by histology, stage, or biomarker status, limiting precision in counseling patients.